{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:13:38Z","timestamp":1786115618885,"version":"build-2736575974"},"reference-count":235,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Schizophrenia is a heterogeneous chronic brain disorder driven by\nmultiple pathophysiological processes. While dopaminergic theories dominate current therapies,\nemerging evidence highlights glutamatergic dysregulation, particularly N-methyl-D-aspartate\nreceptor (NMDAR) hypofunction, as a key mechanism alongside dopaminergic, serotonergic, and\nneurodevelopmental pathways. This article synthesizes mechanistic insights, focusing on\nneurotransmitter disruptions, oxidative stress, neuroinflammation, and Wnt signaling, to elucidate\nthe clinical diversity of schizophrenia and identify biomarkers for precise diagnostics and\ntherapeutics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted using Web of Science, Scopus,\nGoogle Scholar, and PubMed, with keywords including \u201cschizophrenia,\u201d \u201cpsychosis,\u201d\n\u201cpathophysiology,\u201d \u201cmechanism,\u201d and \u201cbiomarker.\u201d Studies were selected to explore NMDAR\nhypofunction, glutamatergic dysregulation, and associated signaling pathways, integrating\npreclinical and human data to map circuit-based interactions and biomarker profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We present a novel circuit-based model of schizophrenia pathophysiology, centered on\nNMDAR hypofunction and glutamatergic dysregulation, integrating dopaminergic, GABAergic,\nand inflammatory pathways. Key biomarkers, including inflammatory (e.g., high-sensitivity Creactive\nprotein [hs-CRP], interleukin-6 [IL-6]), neurochemical (e.g., brain-derived neurotrophic\nfactor [BDNF]), and functional (e.g., mismatch negativity [MMN]), are categorized by\nsymptomatic domains and clinical stages, providing diagnostic and prognostic insights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussions:<\/jats:title>\n                    <jats:p>The findings underscore NMDAR hypofunction\u2019s role in driving schizophrenia\u2019s\nsymptomatic spectrum, though its interplay with other pathways highlights the disorder\u2019s\ncomplexity. Neuronal loss, although not universal, is context-specific (e.g., hippocampal\ninterneurons), complementing functional biomarkers such as MMN. Limitations include the need\nfor robust human validation of biomarkers and broader exploration of non-glutamatergic\nmechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Considering the multifaceted nature of the disorder, our emphasis on the NMDAR\nhypofunction model can help explain many of the synergies involved among the seemingly independent\ndysregulated events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115680266389476250818112814","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T03:54:02Z","timestamp":1761796442000},"page":"1084-1108","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Schizophrenia Pathophysiology: Neurotransmitter Dysfunctions and Biomarker Frontiers"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-6317","authenticated-orcid":true,"given":"Acharya","family":"Balkrishna","sequence":"first","affiliation":[{"name":"Patanjali Herbal Research Department, Patanjali Research Foundation, Haridwar, Uttarakhand, India"},{"name":"Departmentof Applied &amp; Allied Sciences, University of Patanjali, Patanjali Yogpeeth, Haridwar-249405, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-111X","authenticated-orcid":true,"given":"Sumit Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Patanjali Herbal Research Department, Patanjali Research Foundation, Haridwar, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6323-9284","authenticated-orcid":true,"given":"Sonam","family":"Verma","sequence":"additional","affiliation":[{"name":"Patanjali Herbal Research Department, Patanjali Research Foundation, Haridwar, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratha","family":"Bora","sequence":"additional","affiliation":[{"name":"Patanjali Herbal Research Department, Patanjali Research Foundation, Haridwar, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhi","family":"Dobhal","sequence":"additional","affiliation":[{"name":"Patanjali Herbal Research Department, Patanjali Research Foundation, Haridwar, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7562-1731","authenticated-orcid":true,"given":"Vedpriya","family":"Arya","sequence":"additional","affiliation":[{"name":"Patanjali Herbal Research Department, Patanjali Research Foundation, Haridwar, Uttarakhand, India"},{"name":"Departmentof Applied &amp; Allied Sciences, University of Patanjali, Patanjali Yogpeeth, Haridwar-249405, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/molecules23082087","volume":"23","author":"St\u0119pnicki P.","year":"2018","unstructured":"St\u0119pnicki P.; Kondej M.; Kaczor A.A.; Current concepts and treatments of schizophrenia. Molecules  2018,23(8),2087","journal-title":"Molecules"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"18488","DOI":"10.1073\/pnas.1104807108","volume":"108","author":"Allen J.A.","year":"2011","unstructured":"Allen J.A.; Yost J.M.; Setola V.; Chen X.; Sassano M.F.; Chen M.; Peterson S.; Yadav P.N.; Huang X.; Feng B.; Jensen N.H.; Che X.; Bai X.; Frye S.V.; Wetsel W.C.; Caron M.G.; Javitch J.A.; Roth B.L.; Jin J.; Discovery of \u03b2-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA   https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.11048071082011,108(45),18488-18493","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"Carbon M.","year":"2014","unstructured":"Carbon M.; Correll C.U.; Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci  2014,16(4),505-524","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","volume":"17","author":"Stroup T.S.","year":"2018","unstructured":"Stroup T.S.; Gray N.; Management of common adverse effects of antipsychotic medications. World Psychiatry  2018,17(3),341-356","journal-title":"World Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.31887\/DCNS.2000.2.4\/tstroup","volume":"2","author":"Stroup T.S.A.","year":"2000","unstructured":"Stroup T.S.A.; A Lieberman J.; S Swartz M.; McEvoy J.P.; Comparative effectiveness of antipsychotic drugs in schizophrenia. Dialogues Clin Neurosci  2000,2(4),373-379","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"Kirkpatrick B.","year":"2006","unstructured":"Kirkpatrick B.; Fenton W.S.; Carpenter W.T.; Marder S.R.; The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull  2006,32(2),214-219","journal-title":"Schizophr Bull"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","volume":"64","author":"Goldberg T.E.","year":"2007","unstructured":"Goldberg T.E.; Goldman R.S.; Burdick K.E.; Malhotra A.K.; Lencz T.; Patel R.C.; Woerner M.G.; Schooler N.R.; Kane J.M.; Robinson D.G.; Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry  2007,64(10),1115-1122","journal-title":"Arch Gen Psychiatry"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1444843","volume":"15","author":"Li Y.","year":"2024","unstructured":"Li Y.; Ang M.S.; Yee J.Y.; See Y.M.; Lee J.; Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition. Front Psychiatry  2024,15","journal-title":"Front Psychiatry"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","volume":"161","author":"Meltzer H.Y.","year":"2004","unstructured":"Meltzer H.Y.; Arvanitis L.; Bauer D.; Rein W.; Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry  2004,161(6),975-984","journal-title":"Am J Psychiatry"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/S0893-133X(99)00123-2","volume":"21","author":"Geyer M.","year":"1999","unstructured":"Geyer M.; Krebs-Thomson K.; Varty G.B.; The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology  1999,21(6),S134-S142","journal-title":"Neuropsychopharmacology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/ijms18081689","volume":"18","author":"Yang A.","year":"2017","unstructured":"Yang A.; Tsai S.J.; New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci  2017,18(8),1689","journal-title":"Int J Mol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","volume":"158","author":"Goff D.C.","year":"2001","unstructured":"Goff D.C.; Coyle J.T.; The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry  2001,158(9),1367-1377","journal-title":"Am J Psychiatry"},{"key":"ref=13","first-page":"1821","volume":"75","year":"2007","unstructured":"NORTH SW, SHIELDS CG. Schizophrenia: A Review. Am Fam Physician   https:\/\/www.aafp.org\/pubs\/afp\/issues\/2007\/0615\/p1821.html[Internet]2007,75,1821-1829","journal-title":"Am Fam Physician"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2023.04.011","volume":"256","author":"Brasso C.","year":"2023","unstructured":"Brasso C.; Bellino S.; Bozzatello P.; Del Favero E.; Montemagni C.; Rocca P.; Inter-relationships among psychopathology, cognition, and real-life functioning in early and late phase schizophrenia: A network analysis approach. Schizophr Res  2023,256,8-16","journal-title":"Schizophr Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.schres.2023.03.046","volume":"255","author":"Zhang G.","year":"2023","unstructured":"Zhang G.; Ye X.; Wang X.; Lin Y.; Zhu C.; Pan J.; Yin X.; Ye M.; Lv W.; Tang W.; Liu J.; Yang X.; Hui L.; Zheng K.; Serum total cholesterol levels associated with immediate memory performance in patients with chronic schizophrenia. Schizophr Res  2023,255,256-260","journal-title":"Schizophr Res"},{"key":"ref=16","year":"2015","unstructured":"Depressive Disorders DSM-5\u00ae Selections  2015","journal-title":"DSM-5\u00ae Selections"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"Charlson F.J.","year":"2018","unstructured":"Charlson F.J.; Ferrari A.J.; Santomauro D.F.; Diminic S.; Stockings E.; Scott J.G.; McGrath J.J.; Whiteford H.A.; Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr Bull  2018,44(6),1195-1203","journal-title":"Schizophr Bull"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"Vos T.","year":"2017","unstructured":"Vos T.; Abajobir A.A.; Abate K.H.; Abbafati C.; Abbas K.M.; Abd-Allah F.; Abdulkader R.S.; Abdulle A.M.; Abebo T.A.; Abera S.F.; Aboyans V.; Abu-Raddad L.J.; Ackerman I.N.; Adamu A.A.; Adetokunboh O.; Afarideh M.; Afshin A.; Agarwal S.K.; Aggarwal R.; Agrawal A.; Agrawal S.; Ahmadieh H.; Ahmed M.B.; Aichour M.T.E.; Aichour A.N.; Aichour I.; Aiyar S.; Akinyemi R.O.; Akseer N.; Al Lami F.H.; Alahdab F.; Al-Aly Z.; Alam K.; Alam N.; Alam T.; Alasfoor D.; Alene K.A.; Ali R.; Alizadeh-Navaei R.; Alkerwi A.; Alla F.; Allebeck P.; Allen C.; Al-Maskari F.; Al-Raddadi R.; Alsharif U.; Alsowaidi S.; Altirkawi K.A.; Amare A.T.; Amini E.; Ammar W.; Amoako Y.A.; Andersen H.H.; Antonio C.A.T.; Anwari P.; \u00c4rnl\u00f6v J.; Artaman A.; Aryal K.K.; Asayesh H.; Asgedom S.W.; Assadi R.; Atey T.M.; Atnafu N.T.; Atre S.R.; Avila-Burgos L.; Avokphako E.F.G.A.; Awasthi A.; Bacha U.; Badawi A.; Balakrishnan K.; Banerjee A.; Bannick M.S.; Barac A.; Barber R.M.; Barker-Collo S.L.; B\u00e4rnighausen T.; Barquera S.; Barregard L.; Barrero L.H.; Basu S.; Battista B.; Battle K.E.; Baune B.T.; Bazargan-Hejazi S.; Beardsley J.; Bedi N.; Beghi E.; B\u00e9jot Y.; Bekele B.B.; Bell M.L.; Bennett D.A.; Bensenor I.M.; Benson J.; Berhane A.; Berhe D.F.; Bernab\u00e9 E.; Betsu B.D.; Beuran M.; Beyene A.S.; Bhala N.; Bhansali A.; Bhatt S.; Bhutta Z.A.; Biadgilign S.; Bicer B.K.; Bienhoff K.; Bikbov B.; Birungi C.; Biryukov S.; Bisanzio D.; Bizuayehu H.M.; Boneya D.J.; Boufous S.; Bourne R.R.A.; Brazinova A.; Brugha T.S.; Buchbinder R.; Bulto L.N.B.; Bumgarner B.R.; Butt Z.A.; Cahuana-Hurtado L.; Cameron E.; Car M.; Carabin H.; Carapetis J.R.; C\u00e1rdenas R.; Carpenter D.O.; Carrero J.J.; Carter A.; Carvalho F.; Casey D.C.; Caso V.; Casta\u00f1eda-Orjuela C.A.; Castle C.D.; Catal\u00e1-L\u00f3pez F.; Chang H-Y.; Chang J-C.; Charlson F.J.; Chen H.; Chibalabala M.; Chibueze C.E.; Chisumpa V.H.; Chitheer A.A.; Christopher D.J.; Ciobanu L.G.; Cirillo M.; Colombara D.; Cooper C.; Cortesi P.A.; Criqui M.H.; Crump J.A.; Dadi A.F.; Dalal K.; Dandona L.; Dandona R.; das Neves, J.; Davitoiu, D.V.; de Courten, B.; De Leo, D.D.; Defo, B.K.; Degenhardt, L.; Deiparine, S.; Dellavalle, R.P.; Deribe, K.; Des Jarlais, D.C.; Dey, S.; Dharmaratne, S.D.; Dhillon, P.K.; Dicker, D.; Ding, E.L.; Djalalinia, S.; Do, H.P.; Dorsey, E.R.; dos Santos, K.P.B.; Douwes-Schultz, D.; Doyle, K.E.; Driscoll, T.R.; Dubey, M.; Duncan, B.B.; El-Khatib, Z.Z.; Ellerstrand, J.; Enayati, A.; Endries, A.Y.; Ermakov, S.P.; Erskine, H.E.; Eshrati, B.; Eskandarieh, S.; Esteghamati, A.; Estep, K.; Fanuel, F.B.B.; Farinha, C.S.E.S.; Faro, A.; Farzadfar, F.; Fazeli, M.S.; Feigin, V.L.; Fereshtehnejad, S-M.; Fernandes, J.C.; Ferrari, A.J.; Feyissa, T.R.; Filip, I.; Fischer, F.; Fitzmaurice, C.; Flaxman, A.D.; Flor, L.S.; Foigt, N.; Foreman, K.J.; Franklin, R.C.; Fullman, N.; F\u00fcrst, T.; Furtado, J.M.; Futran, N.D.; Gakidou, E.; Ganji, M.; Garcia-Basteiro, A.L.; Gebre, T.; Gebrehiwot, T.T.; Geleto, A.; Gemechu, B.L.; Gesesew, H.A.; Gething, P.W.; Ghajar, A.; Gibney, K.B.; Gill, P.S.; Gillum, R.F.; Ginawi, I.A.M.; Giref, A.Z.; Gishu, M.D.; Giussani, G.; Godwin, W.W.; Gold, A.L.; Goldberg, E.M.; Gona, P.N.; Goodridge, A.; Gopalani, S.V.; Goto, A.; Goulart, A.C.; Griswold, M.; Gugnani, H.C.; Gupta, R.; Gupta, R.; Gupta, T.; Gupta, V.; Hafezi-Nejad, N.; Hailu, G.B.; Hailu, A.D.; Hamadeh, R.R.; Hamidi, S.; Handal, A.J.; Hankey, G.J.; Hanson, S.W.; Hao, Y.; Harb, H.L.; Hareri, H.A.; Haro, J.M.; Harvey, J.; Hassanvand, M.S.; Havmoeller, R.; Hawley, C.; Hay, S.I.; Hay, R.J.; Henry, N.J.; Heredia-Pi, I.B.; Hernandez, J.M.; Heydarpour, P.; Hoek, H.W.; Hoffman, H.J.; Horita, N.; Hosgood, H.D.; Hostiuc, S.; Hotez, P.J.; Hoy, D.G.; Htet, A.S.; Hu, G.; Huang, H.; Huynh, C.; Iburg, K.M.; Igumbor, E.U.; Ikeda, C.; Irvine, C.M.S.; Jacobsen, K.H.; Jahanmehr, N.; Jakovljevic, M.B.; Jassal, S.K.; Javanbakht, M.; Jayaraman, S.P.; Jeemon, P.; Jensen, P.N.; Jha, V.; Jiang, G.; John, D.; Johnson, S.C.; Johnson, C.O.; Jonas, J.B.; J\u00fcrisson, M.; Kabir, Z.; Kadel, R.; Kahsay, A.; Kamal, R.; Kan, H.; Karam, N.E.; Karch, A.; Karema, C.K.; Kasaeian, A.; Kassa, G.M.; Kassaw, N.A.; Kassebaum, N.J.; Kastor, A.; Katikireddi, S.V.; Kaul, A.; Kawakami, N.; Keiyoro, P.N.; Kengne, A.P.; Keren, A.; Khader, Y.S.; Khalil, I.A.; Khan, E.A.; Khang, Y-H.; Khosravi, A.; Khubchandani, J.; Kiadaliri, A.A.; Kieling, C.; Kim, Y.J.; Kim, D.; Kim, P.; Kimokoti, R.W.; Kinfu, Y.; Kisa, A.; Kissimova-Skarbek, K.A.; Kivimaki, M.; Knudsen, A.K.; Kokubo, Y.; Kolte, D.; Kopec, J.A.; Kosen, S.; Koul, P.A.; Koyanagi, A.; Kravchenko, M.; Krishnaswami, S.; Krohn, K.J.; Kumar, G.A.; Kumar, P.; Kumar, S.; Kyu, H.H.; Lal, D.K.; Lalloo, R.; Lambert, N.; Lan, Q.; Larsson, A.; Lavados, P.M.; Leasher, J.L.; Lee, P.H.; Lee, J-T.; Leigh, J.; Leshargie, C.T.; Leung, J.; Leung, R.; Levi, M.; Li, Y.; Li, Y.; Li Kappe, D.; Liang, X.; Liben, M.L.; Lim, S.S.; Linn, S.; Liu, P.Y.; Liu, A.; Liu, S.; Liu, Y.; Lodha, R.; Logroscino, G.; London, S.J.; Looker, K.J.; Lopez, A.D.; Lorkowski, S.; Lotufo, P.A.; Low, N.; Lozano, R.; Lucas, T.C.D.; Macarayan, E.R.K.; Magdy Abd El Razek, H.; Magdy Abd El Razek, M.; Mahdavi, M.; Majdan, M.; Majdzadeh, R.; Majeed, A.; Malekzadeh, R.; Malhotra, R.; Malta, D.C.; Mamun, A.A.; Manguerra, H.; Manhertz, T.; Mantilla, A.; Mantovani, L.G.; Mapoma, C.C.; Marczak, L.B.; Martinez-Raga, J.; Martins-Melo, F.R.; Martopullo, I.; M\u00e4rz, W.; Mathur, M.R.; Mazidi, M.; McAlinden, C.; McGaughey, M.; McGrath, J.J.; McKee, M.; McNellan, C.; Mehata, S.; Mehndiratta, M.M.; Mekonnen, T.C.; Memiah, P.; Memish, Z.A.; Mendoza, W.; Mengistie, M.A.; Mengistu, D.T.; Mensah, G.A.; Meretoja, T.J.; Meretoja, A.; Mezgebe, H.B.; Micha, R.; Millear, A.; Miller, T.R.; Mills, E.J.; Mirarefin, M.; Mirrakhimov, E.M.; Misganaw, A.; Mishra, S.R.; Mitchell, P.B.; Mohammad, K.A.; Mohammadi, A.; Mohammed, K.E.; Mohammed, S.; Mohanty, S.K.; Mokdad, A.H.; Mollenkopf, S.K.; Monasta, L.; Montico, M.; Moradi-Lakeh, M.; Moraga, P.; Mori, R.; Morozoff, C.; Morrison, S.D.; Moses, M.; Mountjoy-Venning, C.; Mruts, K.B.; Mueller, U.O.; Muller, K.; Murdoch, M.E.; Murthy, G.V.S.; Musa, K.I.; Nachega, J.B.; Nagel, G.; Naghavi, M.; Naheed, A.; Naidoo, K.S.; Naldi, L.; Nangia, V.; Natarajan, G.; Negasa, D.E.; Negoi, R.I.; Negoi, I.; Newton, C.R.; Ngunjiri, J.W.; Nguyen, T.H.; Nguyen, Q.L.; Nguyen, C.T.; Nguyen, G.; Nguyen, M.; Nichols, E.; Ningrum, D.N.A.; Nolte, S.; Nong, V.M.; Norrving, B.; Noubiap, J.J.N.; O\u2019Donnell, M.J.; Ogbo, F.A.; Oh, I-H.; Okoro, A.; Oladimeji, O.; Olagunju, T.O.; Olagunju, A.T.; Olsen, H.E.; Olusanya, B.O.; Olusanya, J.O.; Ong, K.; Opio, J.N.; Oren, E.; Ortiz, A.; Osgood-Zimmerman, A.; Osman, M.; Owolabi, M.O.; Pa, M.; Pacella, R.E.; Pana, A.; Panda, B.K.; Papachristou, C.; Park, E-K.; Parry, C.D.; Parsaeian, M.; Patten, S.B.; Patton, G.C.; Paulson, K.; Pearce, N.; Pereira, D.M.; Perico, N.; Pesudovs, K.; Peterson, C.B.; Petzold, M.; Phillips, M.R.; Pigott, D.M.; Pillay, J.D.; Pinho, C.; Plass, D.; Pletcher, M.A.; Popova, S.; Poulton, R.G.; Pourmalek, F.; Prabhakaran, D.; Prasad, N.M.; Prasad, N.; Purcell, C.; Qorbani, M.; Quansah, R.; Quintanilla, B.P.A.; Rabiee, R.H.S.; Radfar, A.; Rafay, A.; Rahimi, K.; Rahimi-Movaghar, A.; Rahimi-Movaghar, V.; Rahman, M.H.U.; Rahman, M.; Rai, R.K.; Rajsic, S.; Ram, U.; Ranabhat, C.L.; Rankin, Z.; Rao, P.C.; Rao, P.V.; Rawaf, S.; Ray, S.E.; Reiner, R.C.; Reinig, N.; Reitsma, M.B.; Remuzzi, G.; Renzaho, A.M.N.; Resnikoff, S.; Rezaei, S.; Ribeiro, A.L.; Ronfani, L.; Roshandel, G.; Roth, G.A.; Roy, A.; Rubagotti, E.; Ruhago, G.M.; Saadat, S.; Sadat, N.; Safdarian, M.; Safi, S.; Safiri, S.; Sagar, R.; Sahathevan, R.; Salama, J.; Saleem, H.O.B.; Salomon, J.A.; Salvi, S.S.; Samy, A.M.; Sanabria, J.R.; Santomauro, D.; Santos, I.S.; Santos, J.V.; Santric Milicevic, M.M.; Sartorius, B.; Satpathy, M.; Sawhney, M.; Saxena, S.; Schmidt, M.I.; Schneider, I.J.C.; Sch\u00f6ttker, B.; Schwebel, D.C.; Schwendicke, F.; Seedat, S.; Sepanlou, S.G.; Servan-Mori, E.E.; Setegn, T.; Shackelford, K.A.; Shaheen, A.; Shaikh, M.A.; Shamsipour, M.; Shariful Islam, S.M.; Sharma, J.; Sharma, R.; She, J.; Shi, P.; Shields, C.; Shifa, G.T.; Shigematsu, M.; Shinohara, Y.; Shiri, R.; Shirkoohi, R.; Shirude, S.; Shishani, K.; Shrime, M.G.; Sibai, A.M.; Sigfusdottir, I.D.; Silva, D.A.S.; Silva, J.P.; Silveira, D.G.A.; Singh, J.A.; Singh, N.P.; Sinha, D.N.; Skiadaresi, E.; Skirbekk, V.; Slepak, E.L.; Sligar, A.; Smith, D.L.; Smith, M.; Sobaih, B.H.A.; Sobngwi, E.; Sorensen, R.J.D.; Sousa, T.C.M.; Sposato, L.A.; Sreeramareddy, C.T.; Srinivasan, V.; Stanaway, J.D.; Stathopoulou, V.; Steel, N.; Stein, M.B.; Stein, D.J.; Steiner, T.J.; Steiner, C.; Steinke, S.; Stokes, M.A.; Stovner, L.J.; Strub, B.; Subart, M.; Sufiyan, M.B.; Sunguya, B.F.; Sur, P.J.; Swaminathan, S.; Sykes, B.L.; Sylte, D.O.; Tabar\u00e9s-Seisdedos, R.; Taffere, G.R.; Takala, J.S.; Tandon, N.; Tavakkoli, M.; Taveira, N.; Taylor, H.R.; Tehrani-Banihashemi, A.; Tekelab, T.; Terkawi, A.S.; Tesfaye, D.J.; Tesssema, B.; Thamsuwan, O.; Thomas, K.E.; Thrift, A.G.; Tiruye, T.Y.; Tobe-Gai, R.; Tollanes, M.C.; Tonelli, M.; Topor-Madry, R.; Tortajada, M.; Touvier, M.; Tran, B.X.; Tripathi, S.; Troeger, C.; Truelsen, T.; Tsoi, D.; Tuem, K.B.; Tuzcu, E.M.; Tyrovolas, S.; Ukwaja, K.N.; Undurraga, E.A.; Uneke, C.J.; Updike, R.; Uthman, O.A.; Uzochukwu, B.S.C.; van Boven, J.F.M.; Varughese, S.; Vasankari, T.; Venkatesh, S.; Venketasubramanian, N.; Vidavalur, R.; Violante, F.S.; Vladimirov, S.K.; Vlassov, V.V.; Vollset, S.E.; Wadilo, F.; Wakayo, T.; Wang, Y-P.; Weaver, M.; Weichenthal, S.; Weiderpass, E.; Weintraub, R.G.; Werdecker, A.; Westerman, R.; Whiteford, H.A.; Wijeratne, T.; Wiysonge, C.S.; Wolfe, C.D.A.; Woodbrook, R.; Woolf, A.D.; Workicho, A.; Xavier, D.; Xu, G.; Yadgir, S.; Yaghoubi, M.; Yakob, B.; Yan, L.L.; Yano, Y.; Ye, P.; Yimam, H.H.; Yip, P.; Yonemoto, N.; Yoon, S-J.; Yotebieng, M.; Younis, M.Z.; Zaidi, Z.; Zaki, M.E.S.; Zegeye, E.A.; Zenebe, Z.M.; Zhang, X.; Zhou, M.; Zipkin, B.; Zodpey, S.; Zuhlke, L.J.; Murray, C.J.L. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet  2017,390(10100),1211-1259","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","volume":"4","author":"Hjorth\u00f8j C.","year":"2017","unstructured":"Hjorth\u00f8j C.; St\u00fcrup A.E.; McGrath J.J.; Nordentoft M.; Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry  2017,4(4),295-301","journal-title":"Lancet Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/BF03391676","volume":"34","author":"Burns J.K.","year":"2012","unstructured":"Burns J.K.; The Social Determinants of Schizophrenia: An African Journey in Social Epidemiology. Public Health Rev  2012,34(2),8","journal-title":"Public Health Rev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1111\/ejn.16050","volume":"58","author":"Balkrishna A.","year":"2023","unstructured":"Balkrishna A.; Verma S.; Singh S.K.; Arya V.; Alzheimer\u2019s disease: A role of biomarkers in early diagnosis and evidences from African ethnomedicinal knowledge. Eur J Neurosci  2023,58(1),2406-2425","journal-title":"Eur J Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1176\/appi.ajp.157.7.1041","volume":"157","author":"Tsuang M.T.","year":"2000","unstructured":"Tsuang M.T.; Stone W.S.; Faraone S.V.; Toward reformulating the diagnosis of schizophrenia. Am J Psychiatry  2000,157(7),1041-1050","journal-title":"Am J Psychiatry"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s43045-024-00397-7","volume":"31","author":"Ahmed G.K.","year":"2024","unstructured":"Ahmed G.K.; Ramadan H.K.A.; Elbeh K.; Haridy N.A.; The role of infections and inflammation in schizophrenia: Review of the evidence. Middle East Curr Psychiatry  2024,31,9","journal-title":"Middle East Curr Psychiatry"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.schres.2009.01.016","volume":"109","author":"Allen A.J.","year":"2009","unstructured":"Allen A.J.; Griss M.E.; Folley B.S.; Hawkins K.A.; Pearlson G.D.; Endophenotypes in schizophrenia: A selective review. Schizophr Res  2009,109(1-3),24-37","journal-title":"Schizophr Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.schres.2023.03.023","volume":"255","author":"Tishler T.A.","year":"2023","unstructured":"Tishler T.A.; Ellingson B.M.; Salvadore G.; Baker P.; Turkoz I.; Subotnik K.L.; de la Fuente-Sandoval C.; Nuechterlein K.H.; Alphs L.; Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study. Schizophr Res  2023,255,195-202","journal-title":"Schizophr Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jpsychires.2004.08.002","volume":"39","author":"McCreadie R.G.","year":"2005","unstructured":"McCreadie R.G.; Srinivasan T.N.; Padmavati R.; Thara R.; Extrapyramidal symptoms in unmedicated schizophrenia. J Psychiatr Res  2005,39(3),261-266","journal-title":"J Psychiatr Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.biopha.2018.06.043","volume":"105","author":"Yadav M.","year":"2018","unstructured":"Yadav M.; Parle M.; Sharma N.; Jindal D.K.; Bhidhasra A.; Dhingra M.S.; Kumar A.; Dhingra S.; Protective effects of Spinacia oleracea seeds extract in an experimental model of schizophrenia: Possible behavior, biochemical, neurochemical and cellular alterations. Biomed Pharmacother  2018,105,1015-1025","journal-title":"Biomed Pharmacother"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.64719\/pb.4584","volume":"49","author":"Girdler S.J.","year":"2019","unstructured":"Girdler S.J.; Confino J.E.; Woesner M.E.; Exercise as a treatment for schizophrenia: A review. Psychopharmacol Bull  2019,49,56","journal-title":"Psychopharmacol Bull"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.euroneuro.2008.04.002","volume":"18","author":"Murray R.M.","year":"2008","unstructured":"Murray R.M.; Lappin J.; Di Forti M.; Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol  2008,18,S129-S134.(Suppl. 3)","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"Leucht S.","year":"2009","unstructured":"Leucht S.; Corves C.; Arbter D.; Engel R.R.; Li C.; Davis J.M.; Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet  2009,373(9657),31-41","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bbr.2007.12.032","volume":"189","author":"Featherstone R.E.","year":"2008","unstructured":"Featherstone R.E.; Rizos Z.; Kapur S.; Fletcher P.J.; A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behav Brain Res  2008,189(1),170-179","journal-title":"Behav Brain Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","volume":"363","author":"Mueser K.T.","year":"2004","unstructured":"Mueser K.T.; McGurk S.R.; Schizophrenia. Lancet  2004,363(9426),2063-2072","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/schbul\/sbs100","volume":"38","author":"Javitt D.C.","year":"2012","unstructured":"Javitt D.C.; Twenty-five years of glutamate in schizophrenia: Are we there yet? Schizophr Bull  2012,38(5),911-913","journal-title":"Schizophr Bull"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"Jentsch J.","year":"1999","unstructured":"Jentsch J.; Roth R.H.; The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology  1999,20(3),201-225","journal-title":"Neuropsychopharmacology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.pnpbp.2004.06.019","volume":"28","author":"Becker A.","year":"2004","unstructured":"Becker A.; Grecksch G.; Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry  2004,28(8),1267-1277","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s11064-011-0670-4","volume":"37","author":"Chatterjee M.","year":"2012","unstructured":"Chatterjee M.; Singh S.; Kumari R.; Verma A.K.; Palit G.; Evaluation of the antipsychotic potential of Panax quinquefolium in ketamine induced experimental psychosis model in mice. Neurochem Res  2012,37(4),759-770","journal-title":"Neurochem Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.tics.2017.06.006","volume":"21","author":"Forsyth J.K.","year":"2017","unstructured":"Forsyth J.K.; Lewis D.A.; Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: An integrative model for diverse clinical features. Trends Cogn Sci  2017,21(10),760-778","journal-title":"Trends Cogn Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1017\/S1461145707008401","volume":"11","author":"Ng F.","year":"2008","unstructured":"Ng F.; Berk M.; Dean O.; Bush A.I.; Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol  2008,11(6),851-876","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00023210-200115040-00004","volume":"15","author":"Yao J.K.","year":"2001","unstructured":"Yao J.K.; Reddy R.D.; van Kammen D.P.; Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs  2001,15(4),287-310","journal-title":"CNS Drugs"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.neulet.2010.05.088","volume":"479","author":"Padurariu M.","year":"2010","unstructured":"Padurariu M.; Ciobica A.; Dobrin I.; Stefanescu C.; Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett  2010,479(3),317-320","journal-title":"Neurosci Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1124\/pharmrev.120.000131","volume":"73","author":"Hansen K.B.","year":"2021","unstructured":"Hansen K.B.; Wollmuth L.P.; Bowie D.; Furukawa H.; Menniti F.S.; Sobolevsky A.I.; Swanson G.T.; Swanger S.A.; Greger I.H.; Nakagawa T.; McBain C.J.; Jayaraman V.; Low C.M.; Dell\u2019Acqua M.L.; Diamond J.S.; Camp C.R.; Perszyk R.E.; Yuan H.; Traynelis S.F.; Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol Rev  2021,73(4),1469-1658","journal-title":"Pharmacol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.sbi.2019.05.004","volume":"57","author":"Greger I.H.","year":"2019","unstructured":"Greger I.H.; Mayer M.L.; Structural biology of glutamate receptor ion channels: Towards an understanding of mechanism. Curr Opin Struct Biol  2019,57,185-195","journal-title":"Curr Opin Struct Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"Traynelis S.F.","year":"2010","unstructured":"Traynelis S.F.; Wollmuth L.P.; McBain C.J.; Menniti F.S.; Vance K.M.; Ogden K.K.; Hansen K.B.; Yuan H.; Myers S.J.; Dingledine R.; Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol Rev  2010,62(3),405-496","journal-title":"Pharmacol Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola D.","year":"2016","unstructured":"Bugarski-Kirola D.; Iwata N.; Sameljak S.; Reid C.; Blaettler T.; Millar L.; Marques T.R.; Garibaldi G.; Kapur S.; Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry  2016,3(12),1115-1128","journal-title":"Lancet Psychiatry"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","volume":"70","author":"Lane H.Y.","year":"2013","unstructured":"Lane H.Y.; Lin C.H.; Green M.F.; Hellemann G.; Huang C.C.; Chen P.W.; Tun R.; Chang Y.C.; Tsai G.E.; Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry  2013,70(12),1267-1275","journal-title":"JAMA Psychiatry"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nn835","volume":"5","author":"Hardingham G.E.","year":"2002","unstructured":"Hardingham G.E.; Fukunaga Y.; Bading H.; Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci  2002,5(5),405-414","journal-title":"Nat Neurosci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","volume":"98","author":"Reiner A.","year":"2018","unstructured":"Reiner A.; Levitz J.; Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron  2018,98(6),1080-1098","journal-title":"Neuron"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1085\/jgp.201812032","volume":"150","author":"Hansen K.B.","year":"2018","unstructured":"Hansen K.B.; Yi F.; Perszyk R.E.; Furukawa H.; Wollmuth L.P.; Gibb A.J.; Traynelis S.F.; Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol  2018,150(8),1081-1105","journal-title":"J Gen Physiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/schbul\/sbs069","volume":"38","author":"Javitt D.C.","year":"2012","unstructured":"Javitt D.C.; Zukin S.R.; Heresco-Levy U.; Umbricht D.; Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia. Schizophr Bull  2012,38(5),958-966","journal-title":"Schizophr Bull"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/schbul\/sbs076","volume":"38","author":"Coyle J.T.","year":"2012","unstructured":"Coyle J.T.; NMDA receptor and schizophrenia: A brief history. Schizophr Bull  2012,38(5),920-926","journal-title":"Schizophr Bull"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Ripke S.","year":"2014","unstructured":"Ripke S.; Neale B.M.; Corvin A.; Walters J.T.R.; Farh K.H.; Holmans P.A.; Biological insights from 108 schizophrenia-associated genetic loci. Nature  2014,511(7510),421-427","journal-title":"Nature"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/mp.2012.137","volume":"18","author":"Weickert C.S.","year":"2013","unstructured":"Weickert C.S.; Fung S.J.; Catts V.S.; Schofield P.R.; Allen K.M.; Moore L.T.; Newell K.A.; Pellen D.; Huang X-F.; Catts S.V.; Weickert T.W.; Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry  2013,18(11),1185-1192","journal-title":"Mol Psychiatry"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","volume":"98","author":"Mohn A.R.","year":"1999","unstructured":"Mohn A.R.; Gainetdinov R.R.; Caron M.G.; Koller B.H.; Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell  1999,98(4),427-436","journal-title":"Cell"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fpsyt.2018.00566","volume":"9","author":"Lin E.","year":"2018","unstructured":"Lin E.; Lin C.H.; Lai Y.L.; Huang C.H.; Huang Y.J.; Lane H.Y.; Combination of G72 genetic variation and G72 protein level to detect schizophrenia: Machine learning approaches. Front Psychiatry  2018,9,566","journal-title":"Front Psychiatry"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.mp.4001682","volume":"10","author":"Seeman P.","year":"2005","unstructured":"Seeman P.; Ko F.; Tallerico T.; Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry  2005,10(9),877-883","journal-title":"Mol Psychiatry"},{"key":"ref=56","first-page":"320","volume":"21","author":"Deutsch S.I.","year":"1998","unstructured":"Deutsch S.I.; Mastropaolo J.; Rosse R.B.; Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol  1998,21(6),320-332","journal-title":"Clin Neuropharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/schbul\/sby003","volume":"45","author":"Nakao K.","year":"2019","unstructured":"Nakao K.; Jeevakumar V.; Jiang S.Z.; Fujita Y.; Diaz N.B.; Pretell Annan C.A.; Eskow Jaunarajs K.L.; Hashimoto K.; Belforte J.E.; Nakazawa K.; Schizophrenia-like dopamine release abnormalities in a mouse model of NMDA receptor hypofunction. Schizophr Bull  2019,45(1),138-147","journal-title":"Schizophr Bull"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/mp.2011.171","volume":"17","author":"Stone J.M.","year":"2012","unstructured":"Stone J.M.; Dietrich C.; Edden R.; Mehta M.A.; De Simoni S.; Reed L.J.; Krystal J.H.; Nutt D.; Barker G.J.; Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Mol Psychiatry  2012,17(7),664-665","journal-title":"Mol Psychiatry"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"Merritt K.","year":"2016","unstructured":"Merritt K.; Egerton A.; Kempton M.J.; Taylor M.J.; McGuire P.K.; Nature of glutamate alterations in schizophrenia a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry  2016,73(7),665-674","journal-title":"JAMA Psychiatry"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","volume":"27","author":"Homayoun H.","year":"2007","unstructured":"Homayoun H.; Moghaddam B.; NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci  2007,27(43),11496-11500","journal-title":"J Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","volume":"78","author":"Schobel S.A.","year":"2013","unstructured":"Schobel S.A.; Chaudhury N.H.; Khan U.A.; Paniagua B.; Styner M.A.; Asllani I.; Inbar B.P.; Corcoran C.M.; Lieberman J.A.; Moore H.; Small S.A.; Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron  2013,78(1),81-93","journal-title":"Neuron"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/biom10060947","volume":"10","author":"Adell A.","year":"2020","unstructured":"Adell A.; Brain NMDA receptors in schizophrenia and depression. Biomolecules  2020,10(6),947","journal-title":"Biomolecules"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","volume":"31","author":"Lisman J.E.","year":"2008","unstructured":"Lisman J.E.; Coyle J.T.; Green R.W.; Javitt D.C.; Benes F.M.; Heckers S.; Grace A.A.; Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci  2008,31(5),234-242","journal-title":"Trends Neurosci"},{"key":"ref=64","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.44","volume":"6","author":"Bygrave A.M.","year":"2016","unstructured":"Bygrave A.M.; Masiulis S.; Nicholson E.; Berkemann M.; Barkus C.; Sprengel R.; Harrison P.J.; Kullmann D.M.; Bannerman D.M.; K\u00e4tzel D.; Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Transl Psychiatry  2016,6(4)","journal-title":"Transl Psychiatry"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","volume":"50","author":"Schwarcz R.","year":"2001","unstructured":"Schwarcz R.; Rassoulpour A.; Wu H.Q.; Medoff D.; Tamminga C.A.; Roberts R.C.; Increased cortical kynurenate content in schizophrenia. Biol Psychiatry  2001,50(7),521-530","journal-title":"Biol Psychiatry"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/schbul\/sbl033","volume":"33","author":"Chess A.C.","year":"2007","unstructured":"Chess A.C.; Simoni M.K.; Alling T.E.; Bucci D.J.; Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull  2007,33(3),797-804","journal-title":"Schizophr Bull"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/npp.2010.39","volume":"35","author":"Potter M.C.","year":"2010","unstructured":"Potter M.C.; Elmer G.I.; Bergeron R.; Albuquerque E.X.; Guidetti P.; Wu H.Q.; Schwarcz R.; Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology  2010,35(8),1734-1742","journal-title":"Neuropsychopharmacology"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.molbrainres.2004.12.005","volume":"135","author":"Coultrap S.J.","year":"2005","unstructured":"Coultrap S.J.; Nixon K.M.; Alvestad R.M.; Fernando Valenzuela C.; Browning M.D.; Differential expression of NMDA receptor subunits and splice variants among the CA1, CA3 and dentate gyrus of the adult rat. Brain Res Mol Brain Res  2005,135(1-2),104-111","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.biopsych.2004.09.013","volume":"56","author":"Malaspina D.","year":"2004","unstructured":"Malaspina D.; Harkavy-Friedman J.; Corcoran C.; Mujica-Parodi L.; Printz D.; Gorman J.M.; Van Heertum R.; Resting neural activity distinguishes subgroups of schizophrenia patients. Biol Psychiatry  2004,56(12),931-937","journal-title":"Biol Psychiatry"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.neuropharm.2011.01.022","volume":"62","author":"Nakazawa K.","year":"2012","unstructured":"Nakazawa K.; Zsiros V.; Jiang Z.; Nakao K.; Kolata S.; Zhang S.; Belforte J.E.; GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology  2012,62(3),1574-1583","journal-title":"Neuropharmacology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.biopsych.2018.01.018","volume":"84","author":"Pafundo D.E.","year":"2018","unstructured":"Pafundo D.E.; Miyamae T.; Lewis D.A.; Gonzalez-Burgos G.; Presynaptic effects of N-Methyl-D-aspartate receptors enhance parvalbumin cell-mediated inhibition of pyramidal cells in mouse prefrontal cortex. Biol Psychiatry  2018,84(6),460-470","journal-title":"Biol Psychiatry"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","volume":"19","author":"Do K.Q.","year":"2009","unstructured":"Do K.Q.; Cabungcal J.H.; Frank A.; Steullet P.; Cuenod M.; Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol  2009,19(2),220-230","journal-title":"Curr Opin Neurobiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrn.2015.19","volume":"17","author":"Hardingham G.E.","year":"2016","unstructured":"Hardingham G.E.; Do K.Q.; Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci  2016,17(2),125-134","journal-title":"Nat Rev Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","volume":"12","author":"Do K.Q.","year":"2000","unstructured":"Do K.Q.; Trabesinger A.H.; Kirsten-Kr\u00fcger M.; Lauer C.J.; Dydak U.; Hell D.; Holsboer F.; Boesiger P.; Cu\u00e9nod M.; Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci  2000,12(10),3721-3728","journal-title":"Eur J Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/jpm13111526","volume":"13","author":"Carletti B.","year":"2023","unstructured":"Carletti B.; Banaj N.; Piras F.; Boss\u00f9 P.; Schizophrenia and glutathione: A challenging story. J Pers Med  2023,13(11),1526","journal-title":"J Pers Med"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.796466","volume":"12","author":"Palaniyappan L.","year":"2021","unstructured":"Palaniyappan L.; Sabesan P.; Li X.; Luo Q.; Schizophrenia increases variability of the central antioxidant system: A meta-analysis of variance from MRS studies of glutathione. Front Psychiatry  2021,12","journal-title":"Front Psychiatry"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1089\/ars.2010.3453","volume":"15","author":"Matsuzawa D.","year":"2011","unstructured":"Matsuzawa D.; Hashimoto K.; Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal  2011,15(7),2057-2065","journal-title":"Antioxid Redox Signal"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nn2071","volume":"11","author":"Papadia S.","year":"2008","unstructured":"Papadia S.; Soriano F.X.; L\u00e9veill\u00e9 F.; Martel M.A.; Dakin K.A.; Hansen H.H.; Kaindl A.; Sifringer M.; Fowler J.; Stefovska V.; Mckenzie G.; Craigon M.; Corriveau R.; Ghazal P.; Horsburgh K.; Yankner B.A.; Wyllie D.J.A.; Ikonomidou C.; Hardingham G.E.; Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci  2008,11(4),476-487","journal-title":"Nat Neurosci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1089\/ars.2012.4907","volume":"18","author":"Wang X.","year":"2013","unstructured":"Wang X.; Pinto-Duarte A.; Sejnowski T.J.; Behrens M.M.; How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia. Antioxid Redox Signal  2013,18(12),1444-1462","journal-title":"Antioxid Redox Signal"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","volume":"176","author":"Steullet P.","year":"2016","unstructured":"Steullet P.; Cabungcal J.H.; Monin A.; Dwir D.; O\u2019Donnell P.; Cuenod M.; Do K.Q.; Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A \u201ccentral hub\u201d in schizophrenia pathophysiology? Schizophr Res  2016,176(1),41-51","journal-title":"Schizophr Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.biopsych.2012.12.004","volume":"73","author":"Jiang Z.","year":"2013","unstructured":"Jiang Z.; Rompala G.R.; Zhang S.; Cowell R.M.; Nakazawa K.; Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons. Biol Psychiatry  2013,73(10),1024-1034","journal-title":"Biol Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.scog.2017.02.001","volume":"8","author":"Alherz F.","year":"2017","unstructured":"Alherz F.; Alherz M.; Almusawi H.; NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: A newly identified correlation and its effects in schizophrenia. Schizophr Res Cogn  2017,8,1-6","journal-title":"Schizophr Res Cogn"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41537-016-0003-3","volume":"3","author":"Nakazawa K.","year":"2017","unstructured":"Nakazawa K.; Jeevakumar V.; Nakao K.; Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. NPJ Schizophr  2017,3(1),7","journal-title":"NPJ Schizophr"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.physbeh.2014.04.038","volume":"131","author":"Vukadinovic Z.","year":"2014","unstructured":"Vukadinovic Z.; NMDA receptor hypofunction and the thalamus in schizophrenia. Physiol Behav  2014,131,156-159","journal-title":"Physiol Behav"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/archgenpsychiatry.2009.115","volume":"66","author":"Schobel S.A.","year":"2009","unstructured":"Schobel S.A.; Lewandowski N.M.; Corcoran C.M.; Moore H.; Brown T.; Malaspina D.; Small S.A.; Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry  2009,66(9),938-946","journal-title":"Arch Gen Psychiatry"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1148\/radiol.2512081548","volume":"251","author":"Lui S.","year":"2009","unstructured":"Lui S.; Parkes L.M.; Huang X.; Zou K.; Chan R.C.K.; Yang H.; Zou L.; Li D.; Tang H.; Zhang T.; Li X.; Wei Y.; Chen L.; Sun X.; Kemp G.J.; Gong Q.Y.; Depressive disorders: Focally altered cerebral perfusion measured with arterial spin-labeling MR imaging. Radiology  2009,251(2),476-484","journal-title":"Radiology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.eplepsyres.2009.03.017","volume":"85","author":"Elliott B.","year":"2009","unstructured":"Elliott B.; Joyce E.; Shorvon S.; Delusions, illusions and hallucinations in epilepsy: 2. Complex phenomena and psychosis. Epilepsy Res  2009,85(2-3),172-186","journal-title":"Epilepsy Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"11424","DOI":"10.1523\/JNEUROSCI.2847-07.2007","volume":"27","author":"Lodge D.J.","year":"2007","unstructured":"Lodge D.J.; Grace A.A.; Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci  2007,27(42),11424-11430","journal-title":"J Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1176\/ajp.155.6.761","volume":"155","author":"Abi-Dargham A.","year":"1998","unstructured":"Abi-Dargham A.; Gil R.; Krystal J.; Baldwin R.M.; Seibyl J.P.; Bowers M.; van Dyck C.H.; Charney D.S.; Innis R.B.; Laruelle M.; Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry  1998,155(6),761-767","journal-title":"Am J Psychiatry"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nn1944","volume":"10","author":"Ressler K.J.","year":"2007","unstructured":"Ressler K.J.; Mayberg H.S.; Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci  2007,10(9),1116-1124","journal-title":"Nat Neurosci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.schres.2008.06.012","volume":"104","author":"Bauer D.","year":"2008","unstructured":"Bauer D.; Gupta D.; Harotunian V.; Meador-Woodruff J.H.; McCullumsmith R.E.; Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res  2008,104(1-3),108-120","journal-title":"Schizophr Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1523\/JNEUROSCI.0839-04.2004","volume":"24","author":"Kalandadze A.","year":"2004","unstructured":"Kalandadze A.; Wu Y.; Fournier K.; Robinson M.B.; Identification of motifs involved in endoplasmic reticulum retention-forward trafficking of the GLT-1 subtype of glutamate transporter. J Neurosci  2004,24(22),5183-5192","journal-title":"J Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.neuron.2007.03.028","volume":"54","author":"Li B.","year":"2007","unstructured":"Li B.; Woo R.S.; Mei L.; Malinow R.; The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron  2007,54(4),583-597","journal-title":"Neuron"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/sj.mp.4001751","volume":"11","author":"Pilowsky L.S.","year":"2006","unstructured":"Pilowsky L.S.; Bressan R.A.; Stone J.M.; Erlandsson K.; Mulligan R.S.; Krystal J.H.; Ell P.J.; First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry  2006,11(2),118-119","journal-title":"Mol Psychiatry"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0920-9964(98)00138-8","volume":"37","author":"Shelley A.","year":"1999","unstructured":"Shelley A.; Silipo G.; Javitt D.C.; Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: Implications for theories of cortical dysfunction. Schizophr Res  1999,37(1),65-79","journal-title":"Schizophr Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1021\/acschemneuro.9b00288","volume":"10","author":"L\u00f3pez-Gil X.","year":"2019","unstructured":"L\u00f3pez-Gil X.; Jim\u00e9nez-S\u00e1nchez L.; Campa L.; Castro E.; Frago C.; Adell A.; Role of serotonin and noradrenaline in the rapid antidepressant action of ketamine. ACS Chem Neurosci  2019,10(7),3318-3326","journal-title":"ACS Chem Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/cercor\/bhv133","volume":"26","author":"Jim\u00e9nez-S\u00e1nchez L.","year":"2016","unstructured":"Jim\u00e9nez-S\u00e1nchez L.; Casta\u00f1\u00e9 A.; P\u00e9rez-Caballero L.; Grifoll M.; L\u00f3pez-Gil X.; Campa L.; Galofr\u00e9 M.; Berrocoso E.; Adell A.; Activation of AMPA Receptors mediates the antidepressant action of deep brain stimulation of the infralimbic prefrontal cortex. Cereb Cortex  2016,26(6),2778-2789","journal-title":"Cereb Cortex"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","volume":"164","author":"Buchanan R.W.","year":"2007","unstructured":"Buchanan R.W.; Javitt D.C.; Marder S.R.; Schooler N.R.; Gold J.M.; McMahon R.P.; Heresco-Levy U.; Carpenter W.T.; The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry  2007,164(10),1593-1602","journal-title":"Am J Psychiatry"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00002826-198902000-00001","volume":"12","author":"Deutsch S.I.","year":"1989","unstructured":"Deutsch S.I.; Mastropaolo J.; Schwartz B.L.; Rosse R.B.; Morihisa J.M.A.; \u201cglutamatergic hypothesis\u201d of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol  1989,12(1),1-13","journal-title":"Clin Neuropharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1017\/S1461145708009267","volume":"12","author":"L\u00f3pez-Gil X.","year":"2009","unstructured":"L\u00f3pez-Gil X.; Artigas F.; Adell A.; Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol  2009,12(4),487-499","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"Newcomer J.W.","year":"2005","unstructured":"Newcomer J.W.; Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs  2005,19,1-93.(Suppl. 1)","journal-title":"CNS Drugs"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.pbb.2011.03.023","volume":"100","author":"Lin C.H.","year":"2012","unstructured":"Lin C.H.; Lane H.Y.; Tsai G.E.; Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav  2012,100(4),665-677","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","volume":"213","author":"Javitt D.C.","year":"2012","unstructured":"Javitt D.C.; Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol  2012,213(213),367-399","journal-title":"Handb Exp Pharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/sj.mp.4001558","volume":"10","author":"Harrison P.J.","year":"2005","unstructured":"Harrison P.J.; Weinberger D.R.; Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry  2005,10(1),40-68, 5","journal-title":"Mol Psychiatry"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11481-012-9417-5","volume":"7","author":"Inestrosa N.C.","year":"2012","unstructured":"Inestrosa N.C.; Montecinos-Oliva C.; Fuenzalida M.; Wnt signaling: Role in alzheimer disease and schizophrenia. J Neuroimmune Pharmacol  2012,7(4),788-807","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1038\/sj.onc.1210064","volume":"25","author":"De Ferrari G.V.","year":"2006","unstructured":"De Ferrari G.V.; Moon R.T.; The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene  2006,25(57),7545-7553","journal-title":"Oncogene"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","volume":"49","author":"Beaulieu J.M.","year":"2009","unstructured":"Beaulieu J.M.; Gainetdinov R.R.; Caron M.G.; Akt\/GSK3 signaling in the action of psychotropic drug. Annurev Pharmtox  2009,49,327-347","journal-title":"Annurev Pharmtox"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1073\/pnas.0307921101","volume":"101","author":"Beaulieu J.M.","year":"2004","unstructured":"Beaulieu J.M.; Sotnikova T.D.; Yao W.D.; Kockeritz L.; Woodgett J.R.; Gainetdinov R.R.; Caron M.G.; Lithium antagonizes dopamine-dependent behaviors mediated by an AKT\/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA  2004,101(14),5099-5104","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cell.2005.05.012","volume":"122","author":"Beaulieu J.M.","year":"2005","unstructured":"Beaulieu J.M.; Sotnikova T.D.; Marion S.; Lefkowitz R.J.; Gainetdinov R.R.; Caron M.G.; An Akt\/\u03b2-arrestin 2\/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell  2005,122(2),261-273","journal-title":"Cell"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WNR.0b013e32834fab06","volume":"23","author":"Yi H.","year":"2012","unstructured":"Yi H.; Hu J.; Qian J.; Hackam A.S.; Expression of brain-derived neurotrophic factor (BDNF) is regulated by the Wnt signaling pathway. Neuroreport  2012,23,189","journal-title":"Neuroreport"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/ijms18030651","volume":"18","author":"Barron H.","year":"2017","unstructured":"Barron H.; Hafizi S.; Andreazza A.; Mizrahi R.; Neuroinflammation and oxidative stress in psychosis and psychosis risk. Int J Mol Sci  2017,18(3),651","journal-title":"Int J Mol Sci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.schres.2014.04.041","volume":"161","author":"Najjar S.","year":"2015","unstructured":"Najjar S.; Pearlman D.M.; Neuroinflammation and white matter pathology in schizophrenia: Systematic review. Schizophr Res  2015,161(1),102-112","journal-title":"Schizophr Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/membranes11110844","volume":"11","author":"Karabicici M.","year":"2021","unstructured":"Karabicici M.; Azbazdar Y.; Iscan E.; Ozhan G.; Misregulation of wnt signaling pathways at the plasma membrane in brain and metabolic diseases. Membranes  2021,11(11),844","journal-title":"Membranes"},{"key":"ref=114","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.615131","volume":"8","author":"Jridi I.","year":"2021","unstructured":"Jridi I.; Cant\u00e9-Barrett K.; Pike-Overzet K.; Staal F.J.T.; Inflammation and wnt signaling: Target for immunomodulatory therapy? Front Cell Dev Biol  2021,8","journal-title":"Front Cell Dev Biol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.euroneuro.2012.07.007","volume":"23","author":"Costa M.","year":"2013","unstructured":"Costa M.; Squassina A.; Congiu D.; Chillotti C.; Niola P.; Galderisi S.; Pistis M.; Del Zompo M.; Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-\u03b1 gene (PPARA) and schizophrenia. Eur Neuropsychopharmacol  2013,23(7),749-759","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/1389450111314070002","volume":"14","author":"Rolland B.","year":"2013","unstructured":"Rolland B.; Deguil J.; Jardri R.; Cottencin O.; Thomas P.; Bordet R.; Therapeutic prospects of PPARs in psychiatric disorders: A comprehensive review. Curr Drug Targets  2013,14(7),724-732","journal-title":"Curr Drug Targets"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fnins.2015.00372","volume":"9","author":"M\u00fcller N.","year":"2015","unstructured":"M\u00fcller N.; Weidinger E.; Leitner B.; Schwarz M.J.; The role of inflammation in schizophrenia. Front Neurosci  2015,9,372","journal-title":"Front Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pnpbp.2012.07.016","volume":"42","author":"Anderson G.","year":"2013","unstructured":"Anderson G.; Maes M.; Berk M.; Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry  2013,42,101-114","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"Goldsmith D.R.","year":"2016","unstructured":"Goldsmith D.R.; Rapaport M.H.; Miller B.J.; A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry  2016,21(12),1696","journal-title":"Mol Psychiatry"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/schbul\/sbx035","volume":"44","author":"Wang A.K.","year":"2018","unstructured":"Wang A.K.; Miller B.J.; Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons Between schizophrenia, bipolar disorder, and depression. Schizophr Bull  2018,44(1),75-83","journal-title":"Schizophr Bull"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12974-017-0962-y","volume":"14","author":"Boerrigter D.","year":"2017","unstructured":"Boerrigter D.; Weickert T.W.; Lenroot R.; O\u2019Donnell M.; Galletly C.; Liu D.; Burgess M.; Cadiz R.; Jacomb I.; Catts V.S.; Fillman S.G.; Weickert C.S.; Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. J Neuroinflammation  2017,14(1),188","journal-title":"J Neuroinflammation"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pnpbp.2018.04.006","volume":"86","author":"Liemburg E.J.","year":"2018","unstructured":"Liemburg E.J.; Nolte I.M.; Klein H.C.; Knegtering H.; Relation of inflammatory markers with symptoms of psychotic disorders: A large cohort study. Prog Neuropsychopharmacol Biol Psychiatry  2018,86,89-94","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/neu.2018.25","volume":"31","author":"Fathian F.","year":"2019","unstructured":"Fathian F.; L\u00f8berg E.M.; Gjestad R.; Steen V.M.; Kroken R.A.; J\u00f8rgensen H.A.; Johnsen E.; Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatr  2019,31(1),36-45","journal-title":"Acta Neuropsychiatr"},{"key":"ref=124","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.703452","volume":"12","author":"Murray A.J.","year":"2021","unstructured":"Murray A.J.; Rogers J.C.; Katshu M.Z.U.H.; Liddle P.F.; Upthegrove R.; Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry  2021,12","journal-title":"Front Psychiatry"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/schbul\/sby024","volume":"44","author":"M\u00fcller N.","year":"2018","unstructured":"M\u00fcller N.; Inflammation in schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophr Bull  2018,44(5),973-982","journal-title":"Schizophr Bull"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/B978-0-12-387718-5.00012-2","volume":"101","author":"Bahn S.","year":"2011","unstructured":"Bahn S.; Noll R.; Barnes A.; Schwarz E.; Guest P.C.; Challenges of introducing new biomarker products for neuropsychiatric disorders into the market. Int Rev Neurobiol  2011,101,299-327","journal-title":"Int Rev Neurobiol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1155\/2013\/510402","volume":"35","author":"Weickert C.S.","year":"2013","unstructured":"Weickert C.S.; Weickert T.W.; Pillai A.; Buckley P.F.; Biomarkers in schizophrenia: A brief conceptual consideration. Dis Markers  2013,35(1),3-9","journal-title":"Dis Markers"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/321071","volume":"35","author":"Martins-de-Souza D.","year":"2013","unstructured":"Martins-de-Souza D.; Biomarkers for psychiatric disorders: Where are we standing? Dis Markers  2013,35(1),1-2","journal-title":"Dis Markers"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/wps.20440","volume":"16","author":"Owen M.J.","year":"2017","unstructured":"Owen M.J.; O\u2019Donovan M.C.; Schizophrenia and the neurodevelopmental continuum:evidence from genomics. World Psychiatry  2017,16(3),227-235","journal-title":"World Psychiatry"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/aje\/kwg118","volume":"158","author":"Gunnell D.","year":"2003","unstructured":"Gunnell D.; Rasmussen F.; Fouskakis D.; Tynelius P.; Harrison G.; Patterns of fetal and childhood growth and the development of psychosis in young males: a cohort study. Am J Epidemiol  2003,158(4),291-300","journal-title":"Am J Epidemiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1176\/appi.focus.20170046","volume":"16","author":"Goldsmith D.R.","year":"2018","unstructured":"Goldsmith D.R.; Crooks C.L.; Walker E.F.; Cotes R.O.; An update on promising biomarkers in schizophrenia. Focus Am Psychiatr Publ  2018,16(2),153-163","journal-title":"Focus Am Psychiatr Publ"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/brainsci13030490","volume":"13","author":"Wi\u0119d\u0142ocha M.","year":"2023","unstructured":"Wi\u0119d\u0142ocha M.; Zborowska N.; Marcinowicz P.; D\u0119bowska W.; D\u0119bowska M.; Zalewska A.; Maciejczyk M.; Waszkiewicz N.; Szulc A.; Oxidative stress biomarkers among schizophrenia inpatients. Brain Sci  2023,13(3),490","journal-title":"Brain Sci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/7854_2018_88","volume":"44","author":"Upthegrove R.","year":"2019","unstructured":"Upthegrove R.; Khandaker G.M.; Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr Top Behav Neurosci  2019,44,49-66","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2012.01.040","volume":"137","author":"Fraguas D.","year":"2012","unstructured":"Fraguas D.; Gonzalez-Pinto A.; Mic\u00f3 J.A.; Reig S.; Parellada M.; Mart\u00ednez-Cengotitabengoa M.; Castro-Fornieles J.; Rapado-Castro M.; Baeza I.; Janssen J.; Desco M.; Leza J.C.; Arango C.; Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr Res  2012,137(1-3),58-65","journal-title":"Schizophr Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/acps.12718","volume":"135","author":"Walton E.","year":"2017","unstructured":"Walton E.; Hibar D.P.; van Erp T.G.M.; Potkin S.G.; Roiz-Santia\u00f1ez R.; Crespo-Facorro B.; Suarez-Pinilla P.; Van Haren N.E.M.; de Zwarte S.M.C.; Kahn R.S.; Cahn W.; Doan N.T.; J\u00f8rgensen K.N.; Gurholt T.P.; Agartz I.; Andreassen O.A.; Westlye L.T.; Melle I.; Berg A.O.; M\u00f8rch-Johnsen L.; F\u00e6rden A.; Flyckt L.; Fatouros-Bergman H.; J\u00f6nsson E.G.; Hashimoto R.; Yamamori H.; Fukunaga M.; Preda A.; De Rossi P.; Piras F.; Banaj N.; Ciullo V.; Spalletta G.; Gur R.E.; Gur R.C.; Wolf D.H.; Satterthwaite T.D.; Beard L.M.; Sommer I.E.; Koops S.; Gruber O.; Richter A.; Kr\u00e4mer B.; Kelly S.; Donohoe G.; McDonald C.; Cannon D.M.; Corvin A.; Gill M.; Di Giorgio A.; Bertolino A.; Lawrie S.; Nickson T.; Whalley H.C.; Neilson E.; Calhoun V.D.; Thompson P.M.; Turner J.A.; Ehrlich S.; Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. Acta Psychiatr Scand  2017,135(5),439-447","journal-title":"Acta Psychiatr Scand"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/hbm.25307","volume":"42","author":"Fan Y.S.","year":"2021","unstructured":"Fan Y.S.; Li L.; Peng Y.; Li H.; Guo J.; Li M.; Yang S.; Yao M.; Zhao J.; Liu H.; Liao W.; Guo X.; Han S.; Cui Q.; Duan X.; Xu Y.; Zhang Y.; Chen H.; Individual\u2010specific functional connectome biomarkers predict schizophrenia positive symptoms during adolescent brain maturation. Hum Brain Mapp  2021,42(5),1475-1484","journal-title":"Hum Brain Mapp"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/jcm10184156","volume":"10","author":"Juchnowicz D.","year":"2021","unstructured":"Juchnowicz D.; Dzikowski M.; Rog J.; Waszkiewicz N.; Karaku\u0142a K.H.; Zalewska A.; Pro\/Antioxidant state as a potential biomarker of schizophrenia. J Clin Med  2021,10(18),4156","journal-title":"J Clin Med"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/schbul\/sbr069","volume":"39","author":"Marsman A.","year":"2013","unstructured":"Marsman A.; van den Heuvel M.P.; Klomp D.W.J.; Kahn R.S.; Luijten P.R.; Hulshoff Pol H.E.; Glutamate in schizophrenia: A focused review and meta-analysis of H-MRS studies. Schizophr Bull  2013,39(1),120-129","journal-title":"Schizophr Bull"},{"key":"ref=139","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113467","volume":"293","author":"Guidara W.","year":"2020","unstructured":"Guidara W.; Messedi M.; Naifar M.; Maalej M.; Grayaa S.; Omri S.; Ben Thabet J.; Maalej M.; Charfi N.; Ayadi F.; Predictive value of oxidative stress biomarkers in drug free patients with schizophrenia and schizo-affective disorder. Psychiatry Res  2020,293","journal-title":"Psychiatry Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/1570159X16666180119144538","volume":"16","author":"Orsolini L.","year":"2018","unstructured":"Orsolini L.; Sarchione F.; Vellante F.; Fornaro M.; Matarazzo I.; Martinotti G.; Valchera A.; Di Nicola M.; Carano A.; Di Giannantonio M.; Perna G.; Olivieri L.; De Berardis D.; Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Curr Neuropharmacol  2018,16(5),583-606","journal-title":"Curr Neuropharmacol"},{"key":"ref=141","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.1046692","volume":"16","author":"Wang Y.","year":"2022","unstructured":"Wang Y.; Meng W.; Liu Z.; An Q.; Hu X.; Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention. Front Cell Neurosci  2022,16","journal-title":"Front Cell Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41983-023-00627-5","volume":"59","author":"Mahmoud A.M.A.","year":"2023","unstructured":"Mahmoud A.M.A.; Eissa M.A.E.; Kolkaila E.A.; Amer R.A.R.; Kotait M.A.; Mismatch negativity as an early biomarker of cognitive impairment in schizophrenia. Egypt J Neurol Psychiat Neurosurg  2023,59(1),24","journal-title":"Egypt J Neurol Psychiat Neurosurg"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.scog.2015.10.004","volume":"2","author":"Penad\u00e9s R.","year":"2015","unstructured":"Penad\u00e9s R.; Garc\u00eda-Rizo C.; Bioque M.; Gonz\u00e1lez-Rodr\u00edguez A.; Cabrera B.; Mezquida G.; Bernardo M.; The search for new biomarkers for cognition in schizophrenia. Schizophr Res Cogn  2015,2(4),172-178","journal-title":"Schizophr Res Cogn"},{"key":"ref=144","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109673","volume":"95","author":"Fang X.","year":"2019","unstructured":"Fang X.; Chen Y.; Wang Y.; Ren J.; Zhang C.; Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry  2019,95","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neulet.2011.10.042","volume":"505","author":"Noto C.S.","year":"2011","unstructured":"Noto C.S.; Gadelha A.; Belangero S.I.; Smith M.A.C.; de Aguiar B.W.; Panizzuti B.; Mari J.J.; Gama C.S.; Bressan R.A.; Brietzke E.; Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett  2011,505(3),282-285","journal-title":"Neurosci Lett"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12888-023-04718-8","volume":"23","author":"Li S.","year":"2023","unstructured":"Li S.; Lu C.; Kang L.; Li Q.; Chen H.; Zhang H.; Tang Z.; Lin Y.; Bai M.; Xiong P.; Study on correlations of BDNF, PI3K, AKT and CREB levels with depressive emotion and impulsive behaviors in drug-na\u00efve patients with first-episode schizophrenia. BMC Psychiatry  2023,23(1),225","journal-title":"BMC Psychiatry"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.genhosppsych.2021.04.010","volume":"71","author":"Chen X.J.","year":"2021","unstructured":"Chen X.J.; Wang D.M.; Zhou H.X.; Zhu R.R.; Tian Y.; Du Y.X.; Chen J.J.; Chen D.C.; Wang L.; Zhang X.Y.; Association of depressive symptoms with cognitive impairment in patients with never-treated first-episode schizophrenia: Analysis of the Depression in Schizophrenia in China (DISC) study. Gen Hosp Psychiatry  2021,71,108-113","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00406-022-01525-2","volume":"273","author":"Fang X.","year":"2023","unstructured":"Fang X.; Wu Z.; Wen L.; Zhang Y.; Wang D.; Yu L.; Wang Y.; Chen Y.; Chen L.; Liu H.; Tang W.; Zhang X.; Zhang C.; Rumination mediates the relationship between childhood trauma and depressive symptoms in schizophrenia patients. Eur Arch Psychiatry Clin Neurosci  2023,273(5),1085-1094","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nic.2019.09.007","volume":"30","author":"Keshavan M.S.","year":"2020","unstructured":"Keshavan M.S.; Collin G.; Guimond S.; Kelly S.; Prasad K.M.; Lizano P.; Neuroimaging in Schizophrenia. Neuroimaging Clin N Am  2020,30(1),73-83","journal-title":"Neuroimaging Clin N Am"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/1673-5374.286957","volume":"16","author":"Bai H.","year":"2021","unstructured":"Bai H.; Zeng H-M.; Han H-B.; Zhang Q-F.; Application of modern neuroimaging technology in the diagnosis and study of Alzheimer\u2019s disease. Neural Regen Res  2021,16(1),73-79","journal-title":"Neural Regen Res"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-981-32-9721-0_9","volume":"1192","author":"Aydin O.","year":"2019","unstructured":"Aydin O.; Unal Aydin P.; Arslan A.; Development of neuroimaging-based biomarkers in psychiatry. Adv Exp Med Biol  2019,1192,159-195","journal-title":"Adv Exp Med Biol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11920-012-0345-0","volume":"15","author":"Ahmed A.O.","year":"2013","unstructured":"Ahmed A.O.; Buckley P.F.; Hanna M.; Neuroimaging schizophrenia: A picture is worth a thousand words, but is it saying anything important? Curr Psychiatry Rep  2013,15(3),345","journal-title":"Curr Psychiatry Rep"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/wps.20426","volume":"16","author":"McGuire P.","year":"2017","unstructured":"McGuire P.; Dazzan P.; Does neuroimaging have a role in predicting outcomes in psychosis? World Psychiatry  2017,16(2),209-210","journal-title":"World Psychiatry"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1176\/appi.ajp.2020.20030340","volume":"178","author":"Kraguljac N.V.","year":"2021","unstructured":"Kraguljac N.V.; McDonald W.M.; Widge A.S.; Rodriguez C.I.; Tohen M.; Nemeroff C.B.; Neuroimaging biomarkers in Schizophrenia. Am J Psychiatry  2021,178(6),509-521","journal-title":"Am J Psychiatry"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/schbul\/sbu099","volume":"41","author":"Perkins D.O.","year":"2015","unstructured":"Perkins D.O.; Jeffries C.D.; Addington J.; Bearden C.E.; Cadenhead K.S.; Cannon T.D.; Cornblatt B.A.; Mathalon D.H.; McGlashan T.H.; Seidman L.J.; Tsuang M.T.; Walker E.F.; Woods S.W.; Heinssen R.; Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull  2015,41(2),419-428","journal-title":"Schizophr Bull"},{"key":"ref=156","author":"Rubio J.M.","year":"2023","unstructured":"Rubio J.M.; Lencz T.; Cao H.; Kraguljac N.; Dhamala E.; Homan P.; Replication of a neuroimaging biomarker for striatal dysfunction in psychosis. medRxiv  2023","journal-title":"medRxiv"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pscychresns.2019.06.004","volume":"290","author":"Chen X.","year":"2019","unstructured":"Chen X.; Li X.; Yan T.; Dong Q.; Mao Z.; Wang Y.; Yang N.; Zhang Q.; Zhao W.; Zhai J.; Chen M.; Du B.; Deng X.; Ji F.; Xiang Y.T.; Song J.; Wu H.; Dong Q.; Chen C.; Wang C.; Li J.; Network functional connectivity analysis in individuals at ultrahigh risk for psychosis and patients with schizophrenia. Psychiatry Res Neuroimaging  2019,290,51-57","journal-title":"Psychiatry Res Neuroimaging"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biopsych.2018.06.007","volume":"85","author":"Du X.","year":"2019","unstructured":"Du X.; Choa F.S.; Chiappelli J.; Wisner K.M.; Wittenberg G.; Adhikari B.; Bruce H.; Rowland L.M.; Kochunov P.; Hong L.E.; Aberrant middle prefrontal-motor cortex connectivity mediates motor inhibitory biomarker in schizophrenia. Biol Psychiatry  2019,85(1),49-59","journal-title":"Biol Psychiatry"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","volume":"23","author":"Egerton A.","year":"2018","unstructured":"Egerton A.; Broberg B.V.; Van Haren N.; Merritt K.; Barker G.J.; Lythgoe D.J.; Perez-Iglesias R.; Baandrup L.; D\u00fcring S.W.; Sendt K.V.; Stone J.M.; Rostrup E.; Sommer I.E.; Glenth\u00f8j B.; Kahn R.S.; Dazzan P.; McGuire P.; Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: A multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry  2018,23(11),2145-2155","journal-title":"Mol Psychiatry"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.eurpsy.2017.12.001","volume":"50","author":"Frank E.","year":"2018","unstructured":"Frank E.; Maier D.; Pajula J.; Suvitaival T.; Borgan F.; Butz-Ostendorf M.; Fischer A.; Hietala J.; Howes O.; Hy\u00f6tyl\u00e4inen T.; Janssen J.; Laurikainen H.; Moreno C.; Suvisaari J.; Van Gils M.; Ore\u0161i\u010d M.; Platform for systems medicine research and diagnostic applications in psychotic disorders\u2014The METSY project. Eur Psychiatry  2018,50,40-46","journal-title":"Eur Psychiatry"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jamapsychiatry.2018.2530","volume":"75","author":"Fusar-Poli P.","year":"2018","unstructured":"Fusar-Poli P.; Hijazi Z.; Stahl D.; Steyerberg E.W.; The science of prognosis in psychiatry. JAMA Psychiatry  2018,75(12),1289-1297","journal-title":"JAMA Psychiatry"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"Trubetskoy V.","year":"2022","unstructured":"Trubetskoy V.; Pardi\u00f1as A.F.; Qi T.; Panagiotaropoulou G.; Awasthi S.; Bigdeli T.B.; Bryois J.; Chen C.Y.; Dennison C.A.; Hall L.S.; Lam M.; Watanabe K.; Frei O.; Ge T.; Harwood J.C.; Koopmans F.; Magnusson S.; Richards A.L.; Sidorenko J.; Wu Y.; Zeng J.; Grove J.; Kim M.; Li Z.; Voloudakis G.; Zhang W.; Adams M.; Agartz I.; Atkinson E.G.; Agerbo E.; Al Eissa M.; Albus M.; Alexander M.; Alizadeh B.Z.; Alptekin K.; Als T.D.; Amin F.; Arolt V.; Arrojo M.; Athanasiu L.; Azevedo M.H.; Bacanu S.A.; Bass N.J.; Begemann M.; Belliveau R.A.; Bene J.; Benyamin B.; Bergen S.E.; Blasi G.; Bobes J.; Bonassi S.; Braun A.; Bressan R.A.; Bromet E.J.; Bruggeman R.; Buckley P.F.; Buckner R.L.; Bybjerg-Grauholm J.; Cahn W.; Cairns M.J.; Calkins M.E.; Carr V.J.; Castle D.; Catts S.V.; Chambert K.D.; Chan R.C.K.; Chaumette B.; Cheng W.; Cheung E.F.C.; Chong S.A.; Cohen D.; Consoli A.; Cordeiro Q.; Costas J.; Curtis C.; Davidson M.; Davis K.L.; de Haan L.; Degenhardt F.; DeLisi L.E.; Demontis D.; Dickerson F.; Dikeos D.; Dinan T.; Djurovic S.; Duan J.; Ducci G.; Dudbridge F.; Eriksson J.G.; Fa\u00f1an\u00e1s L.; Faraone S.V.; Fiorentino A.; Forstner A.; Frank J.; Freimer N.B.; Fromer M.; Frustaci A.; Gadelha A.; Genovese G.; Gershon E.S.; Giannitelli M.; Giegling I.; Giusti-Rodr\u00edguez P.; Godard S.; Goldstein J.I.; Gonz\u00e1lez Pe\u00f1as J.; Gonz\u00e1lez-Pinto A.; Gopal S.; Gratten J.; Green M.F.; Greenwood T.A.; Guillin O.; G\u00fcl\u00f6ks\u00fcz S.; Gur R.E.; Gur R.C.; Guti\u00e9rrez B.; Hahn E.; Hakonarson H.; Haroutunian V.; Hartmann A.M.; Harvey C.; Hayward C.; Henskens F.A.; Herms S.; Hoffmann P.; Howrigan D.P.; Ikeda M.; Iyegbe C.; Joa I.; Juli\u00e0 A.; K\u00e4hler A.K.; Kam-Thong T.; Kamatani Y.; Karachanak-Yankova S.; Kebir O.; Keller M.C.; Kelly B.J.; Khrunin A.; Kim S.W.; Klovins J.; Kondratiev N.; Konte B.; Kraft J.; Kubo M.; Ku\u010dinskas V.; Ku\u010dinskiene Z.A.; Kusumawardhani A.; Kuzelova-Ptackova H.; Landi S.; Lazzeroni L.C.; Lee P.H.; Legge S.E.; Lehrer D.S.; Lencer R.; Lerer B.; Li M.; Lieberman J.; Light G.A.; Limborska S.; Liu C.M.; L\u00f6nnqvist J.; Loughland C.M.; Lubinski J.; Luykx J.J.; Lynham A.; Macek M.; Mackinnon A.; Magnusson P.K.E.; Maher B.S.; Maier W.; Malaspina D.; Mallet J.; Marder S.R.; Marsal S.; Martin A.R.; Martorell L.; Mattheisen M.; McCarley R.W.; McDonald C.; McGrath J.J.; Medeiros H.; Meier S.; Melegh B.; Melle I.; Mesholam-Gately R.I.; Metspalu A.; Michie P.T.; Milani L.; Milanova V.; Mitjans M.; Molden E.; Molina E.; Molto M.D.; Mondelli V.; Moreno C.; Morley C.P.; Muntan\u00e9 G.; Murphy K.C.; Myin-Germeys I.; Nenadi\u0107 I.; Nestadt G.; Nikitina-Zake L.; Noto C.; Nuechterlein K.H.; O\u2019Brien N.L.; O\u2019Neill F.A.; Oh S.Y.; Olincy A.; Ota V.K.; Pantelis C.; Papadimitriou G.N.; Parellada M.; Paunio T.; Pellegrino R.; Periyasamy S.; Perkins D.O.; Pfuhlmann B.; Pietil\u00e4inen O.; Pimm J.; Porteous D.; Powell J.; Quattrone D.; Quested D.; Radant A.D.; Rampino A.; Rapaport M.H.; Rautanen A.; Reichenberg A.; Roe C.; Roffman J.L.; Roth J.; Rothermundt M.; Rutten B.P.F.; Saker-Delye S.; Salomaa V.; Sanjuan J.; Santoro M.L.; Savitz A.; Schall U.; Scott R.J.; Seidman L.J.; Sharp S.I.; Shi J.; Siever L.J.; Sigurdsson E.; Sim K.; Skarabis N.; Slominsky P.; So H.C.; Sobell J.L.; S\u00f6derman E.; Stain H.J.; Steen N.E.; Steixner-Kumar A.A.; St\u00f6gmann E.; Stone W.S.; Straub R.E.; Streit F.; Strengman E.; Stroup T.S.; Subramaniam M.; Sugar C.A.; Suvisaari J.; Svrakic D.M.; Swerdlow N.R.; Szatkiewicz J.P.; Ta T.M.T.; Takahashi A.; Terao C.; Thibaut F.; Toncheva D.; Tooney P.A.; Torretta S.; Tosato S.; Tura G.B.; Turetsky B.I.; \u00dc\u00e7ok A.; Vaaler A.; van Amelsvoort T.; van Winkel R.; Veijola J.; Waddington J.; Walter H.; Waterreus A.; Webb B.T.; Weiser M.; Williams N.M.; Witt S.H.; Wormley B.K.; Wu J.Q.; Xu Z.; Yolken R.; Zai C.C.; Zhou W.; Zhu F.; Zimprich F.; Atba\u015fo\u011flu E.C.; Ayub M.; Benner C.; Bertolino A.; Black D.W.; Bray N.J.; Breen G.; Buccola N.G.; Byerley W.F.; Chen W.J.; Cloninger C.R.; Crespo-Facorro B.; Donohoe G.; Freedman R.; Galletly C.; Gandal M.J.; Gennarelli M.; Hougaard D.M.; Hwu H.G.; Jablensky A.V.; McCarroll S.A.; Moran J.L.; Mors O.; Mortensen P.B.; M\u00fcller-Myhsok B.; Neil A.L.; Nordentoft M.; Pato M.T.; Petryshen T.L.; Pirinen M.; Pulver A.E.; Schulze T.G.; Silverman J.M.; Smoller J.W.; Stahl E.A.; Tsuang D.W.; Vilella E.; Wang S.H.; Xu S.; Dai N.; Wenwen Q.; Wildenauer D.B.; Agiananda F.; Amir N.; Antoni R.; Arsianti T.; Asmarahadi A.; Diatri H.; Djatmiko P.; Irmansyah I.; Khalimah S.; Kusumadewi I.; Kusumaningrum P.; Lukman P.R.; Nasrun M.W.; Safyuni N.S.; Prasetyawan P.; Semen G.; Siste K.; Tobing H.; Widiasih N.; Wiguna T.; Wulandari D.; Evalina N.; Hananto A.J.; Ismoyo J.H.; Marini T.M.; Henuhili S.; Reza M.; Yusnadewi S.; Abyzov A.; Akbarian S.; Ashley-Koch A.; van Bakel H.; Breen M.; Brown M.; Bryois J.; Carlyle B.; Charney A.; Coetzee G.; Crawford G.; Dracheva S.; Emani P.; Farnham P.; Fromer M.; Galeev T.; Gandal M.; Gerstein M.; Giase G.; Girdhar K.; Goes F.; Grennan K.; Gu M.; Guerra B.; Gursoy G.; Hoffman G.; Hyde T.; Jaffe A.; Jiang S.; Jiang Y.; Kefi A.; Kim Y.; Kitchen R.; Knowles J.A.; Lay F.; Lee D.; Li M.; Liu C.; Liu S.; Mattei E.; Navarro F.; Pan X.; Peters M.A.; Pinto D.; Pochareddy S.; Polioudakis D.; Purcaro M.; Purcell S.; Pratt H.; Reddy T.; Rhie S.; Roussos P.; Rozowsky J.; Sanders S.; Sestan N.; Sethi A.; Shi X.; Shieh A.; Swarup V.; Szekely A.; Wang D.; Warrell J.; Weissman S.; Weng Z.; White K.; Wiseman J.; Witt H.; Won H.; Wood S.; Wu F.; Xu X.; Yao L.; Zandi P.; Arranz M.J.; Bakker S.; Bender S.; Bramon E.; Collier D.A.; Crepo-Facorro B.; Hall J.; Iyegbe C.; Kahn R.; Lawrie S.; Lewis C.; Lin K.; Linszen D.H.; Mata I.; McIntosh A.; Murray R.M.; Ophoff R.A.; van Os J.; Powell J.; Rujescu D.; Walshe M.; Weisbrod M.; Achsel T.; Andres-Alonso M.; Bagni C.; Bay\u00e9s \u00c0.; Biederer T.; Brose N.; Brown T.C.; Chua J.J.E.; Coba M.P.; Cornelisse L.N.; de Jong A.P.H.; de Juan-Sanz J.; Dieterich D.C.; Feng G.; Goldschmidt H.L.; Gundelfinger E.D.; Hoogenraad C.; Huganir R.L.; Hyman S.E.; Imig C.; Jahn R.; Jung H.; Kaeser P.S.; Kim E.; Koopmans F.; Kreutz M.R.; Lipstein N.; MacGillavry H.D.; Malenka R.; McPherson P.S.; O\u2019Connor V.; Pielot R.; Ryan T.A.; Sahasrabudhe D.; Sala C.; Sheng M.; Smalla K-H.; Smit A.B.; S\u00fcdhof T.C.; Thomas P.D.; Toonen R.F.; van Weering J.R.T.; Verhage M.; Verpelli C.; Adolfsson R.; Arango C.; Baune B.T.; Belangero S.I.; B\u00f8rglum A.D.; Braff D.; Bramon E.; Buxbaum J.D.; Campion D.; Cervilla J.A.; Cichon S.; Collier D.A.; Corvin A.; Curtis D.; Forti M.D.; Domenici E.; Ehrenreich H.; Escott-Price V.; Esko T.; Fanous A.H.; Gareeva A.; Gawlik M.; Gejman P.V.; Gill M.; Glatt S.J.; Golimbet V.; Hong K.S.; Hultman C.M.; Hyman S.E.; Iwata N.; J\u00f6nsson E.G.; Kahn R.S.; Kennedy J.L.; Khusnutdinova E.; Kirov G.; Knowles J.A.; Krebs M-O.; Laurent-Levinson C.; Lee J.; Lencz T.; Levinson D.F.; Li Q.S.; Liu J.; Malhotra A.K.; Malhotra D.; McIntosh A.; McQuillin A.; Menezes P.R.; Morgan V.A.; Morris D.W.; Mowry B.J.; Murray R.M.; Nimgaonkar V.; N\u00f6then M.M.; Ophoff R.A.; Paciga S.A.; Palotie A.; Pato C.N.; Qin S.; Rietschel M.; Riley B.P.; Rivera M.; Rujescu D.; Saka M.C.; Sanders A.R.; Schwab S.G.; Serretti A.; Sham P.C.; Shi Y.; St Clair D.; Stef\u00e1nsson H.; Stefansson K.; Tsuang M.T.; van Os J.; Vawter M.P.; Weinberger D.R.; Werge T.; Wildenauer D.B.; Yu X.; Yue W.; Holmans P.A.; Pocklington A.J.; Roussos P.; Vassos E.; Verhage M.; Visscher P.M.; Yang J.; Posthuma D.; Andreassen O.A.; Kendler K.S.; Owen M.J.; Wray N.R.; Daly M.J.; Huang H.; Neale B.M.; Sullivan P.F.; Ripke S.; Walters J.T.R.; O\u2019Donovan M.C.; de Haan L.; van Amelsvoort T.; van Winkel R.; Gareeva A.; Sham P.C.; Shi Y.; St Clair D.; van Os J.; Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature  2022,604(7906),502-508","journal-title":"Nature"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archpsyc.1991.01810350036005","volume":"48","author":"Benes F.M.","year":"1991","unstructured":"Benes F.M.; McSparren J.; Bird E.D.; SanGiovanni J.P.; Vincent S.L.; Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry  1991,48(11),996-1001","journal-title":"Arch Gen Psychiatry"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1176\/appi.ajp.20220676","volume":"180","author":"Dienel S.J.","year":"2023","unstructured":"Dienel S.J.; Fish K.N.; Lewis D.A.; The nature of prefrontal cortical GABA neuron alterations in schizophrenia: Markedly lower somatostatin and parvalbumin gene expression without missing neurons. Am J Psychiatry  2023,180(7),495-507","journal-title":"Am J Psychiatry"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archpsyc.1995.03950160008002","volume":"52","author":"Akbarian S.","year":"1995","unstructured":"Akbarian S.; Kim J.J.; Potkin S.G.; Hagman J.O.; Tafazzoli A.; Bunney W.E.; Jones E.G.; Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry  1995,52(4),258-266","journal-title":"Arch Gen Psychiatry"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0920-9964(02)00297-9","volume":"60","author":"Cullen T.J.","year":"2003","unstructured":"Cullen T.J.; Walker M.A.; Parkinson N.; Craven R.; Crow T.J.; Esiri M.M.; Harrison P.J.; A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr Res  2003,60(2-3),157-166","journal-title":"Schizophr Res"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.schres.2016.08.007","volume":"180","author":"Dorph-Petersen K.A.","year":"2017","unstructured":"Dorph-Petersen K.A.; Lewis D.A.; Postmortem structural studies of the thalamus in schizophrenia. Schizophr Res  2017,180,28-35","journal-title":"Schizophr Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/mp.2010.88","volume":"16","author":"Green M.J.","year":"2011","unstructured":"Green M.J.; Matheson S.L.; Shepherd A.; Weickert C.S.; Carr V.J.; Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-analysis. Mol Psychiatry  2011,16(9),960-972","journal-title":"Mol Psychiatry"},{"key":"ref=169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102370","volume":"54","author":"Singh J.","year":"2020","unstructured":"Singh J.; Verma R.; Raghav R.; Sarkar S.; Sood M.; Jain R.; Brain-derived neurotrophic factor (BDNF) levels in first-episode schizophrenia and healthy controls: A comparative study. Asian J Psychiatr  2020,54","journal-title":"Asian J Psychiatr"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1017\/S0033291719001685","volume":"49","author":"Bora E.","year":"2019","unstructured":"Bora E.; Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: A meta-analysis. Psychol Med  2019,49(12),1971-1979","journal-title":"Psychol Med"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrd3366","author":"Nagahara A.H.","year":"2011","unstructured":"Nagahara A.H.; Tuszynski M.H.; Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov  2011,209","journal-title":"Nat Rev Drug Discov"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jpsychires.2022.10.022","volume":"156","author":"Shi X.J.","year":"2022","unstructured":"Shi X.J.; Du Y.; Lei-Chen; Li, X.S.; Yao, C.Q.; Cheng, Y. Effects of brain-derived neurotrophic factor (BDNF) on the Schizophrenia model of animals. J Psychiatr Res  2022,156,538-546","journal-title":"J Psychiatr Res"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuroscience.2021.11.024","volume":"480","author":"Schmidt M.","year":"2022","unstructured":"Schmidt M.; Rossetti A.C.; Brandwein C.; Riva M.A.; Gass P.; Elsner P.; Hesse-Macabata J.; Hipler U.C.; Smesny S.; Milleit B.; Brain derived neurotrophic factor deficiency is associated with cognitive impairment and elevated phospholipase A2 activity in plasma of mice. Neuroscience  2022,480,167-177","journal-title":"Neuroscience"},{"key":"ref=174","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114200","volume":"305","author":"Shoshina I.I.","year":"2021","unstructured":"Shoshina I.I.; Hovis J.K.; Felisberti F.M.; Santos N.A.; Adreeva A.; Butler P.D.; Fernandes T.P.; Visual processing and BDNF levels in first-episode schizophrenia. Psychiatry Res  2021,305","journal-title":"Psychiatry Res"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/BMI.S4877","volume":"2010","author":"Schwarz E.","year":"2010","unstructured":"Schwarz E.; Izmailov R.; Spain M.; Barnes A.; Mapes J.P.; Guest P.C.; Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights  2010,2010,39","journal-title":"Biomark Insights"},{"key":"ref=176","first-page":"13","author":"Venigalla H.","year":"2017","unstructured":"Venigalla H.; Mekala H.M.; Ahmed R.; Zain H.; Dar S.; Veliz S.S.; Update on Biomarkers in psychiatric disorders - Are we aware, Do we use in our clinical practice? Ment Health Fam Med  2017,13","journal-title":"Ment Health Fam Med"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.schres.2017.09.021","volume":"195","author":"Davison J.","year":"2018","unstructured":"Davison J.; O\u2019Gorman A.; Brennan L.; Cotter D.R.; A systematic review of metabolite biomarkers of schizophrenia. Schizophr Res  2018,195,32-50","journal-title":"Schizophr Res"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-71014-w","volume":"10","author":"Parksepp M.","year":"2020","unstructured":"Parksepp M.; Leppik L.; Koch K.; Uppin K.; Kangro R.; Haring L.; Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease. Sci Rep  2020,10,1-11","journal-title":"Sci Rep"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12888-019-2093-8","volume":"19","author":"Obyedkov I.","year":"2019","unstructured":"Obyedkov I.; Skuhareuskaya M.; Skugarevsky O.; Obyedkov V.; Buslauski P.; Skuhareuskaya T.; Waszkiewicz N.; Saccadic eye movements in different dimensions of schizophrenia and in clinical high-risk state for psychosis. BMC Psychiatry  2019,19(1),110","journal-title":"BMC Psychiatry"},{"key":"ref=180","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.3390\/jcm9082375","volume":"9","author":"Waszkiewicz N.","year":"2020","unstructured":"Waszkiewicz N.; Mentally Sick or Not\u2014(Bio)markers of psychiatric disorders needed. J Clin Med  2020,9,2375","journal-title":"J Clin Med"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.nbd.2006.01.003","volume":"22","author":"Cabungcal J.H.","year":"2006","unstructured":"Cabungcal J.H.; Nicolas D.; Kraftsik R.; Cu\u00e9nod M.; Do K.Q.; Hornung J.P.; Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia. Neurobiol Dis  2006,22(3),624-637","journal-title":"Neurobiol Dis"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","volume":"160","author":"Gottesman I.I.","year":"2003","unstructured":"Gottesman I.I.; Gould T.D.; The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry  2003,160(4),636-645","journal-title":"Am J Psychiatry"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.bandc.2008.09.001","volume":"68","author":"Calkins M.E.","year":"2008","unstructured":"Calkins M.E.; Iacono W.G.; Ones D.S.; Eye movement dysfunction in first-degree relatives of patients with schizophrenia: A meta-analytic evaluation of candidate endophenotypes. Brain Cogn  2008,68(3),436-461","journal-title":"Brain Cogn"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/7854_2010_60","volume":"4","author":"Levy D.L.","year":"2010","unstructured":"Levy D.L.; Sereno A.B.; Gooding D.C.; O\u2019Driscoll G.A.; Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Curr Top Behav Neurosci   https:\/\/link.springer.com\/chapter\/10.1007\/7854_2010_602010,4,311-347","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1038\/s41380-020-0679-7","volume":"25","author":"Andreou C.","year":"2020","unstructured":"Andreou C.; Borgwardt S.; Structural and functional imaging markers for susceptibility to psychosis. Mol Psychiatry  2020,25,2773","journal-title":"Mol Psychiatry"},{"key":"ref=186","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.620401","volume":"12","author":"Merritt K.","year":"2021","unstructured":"Merritt K.; Luque Laguna P.; Irfan A.; David A.S.; Longitudinal structural MRI findings in individuals at genetic and clinical high risk for psychosis: A systematic review. Front Psychiatry  2021,12","journal-title":"Front Psychiatry"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0304-3940(80)90178-0","volume":"20","author":"Kim J.S.","year":"1980","unstructured":"Kim J.S.; Kornhuber H.H.; Schmid-Burgk W.; Holzm\u00fcller B.; Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett  1980,20(3),379-382","journal-title":"Neurosci Lett"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopsych.2010.10.004","volume":"69","author":"Brugger S.","year":"2011","unstructured":"Brugger S.; Davis J.M.; Leucht S.; Stone J.M.; Proton magnetic resonance spectroscopy and illness stage in schizophrenia: A systematic review and meta-analysis. Biol Psychiatry  2011,69(5),495-503","journal-title":"Biol Psychiatry"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/schbul\/sbr180","volume":"39","author":"Fusar-Poli P.","year":"2013","unstructured":"Fusar-Poli P.; Meyer-Lindenberg A.; Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of [(18)F\/(11)C]-DOPA PET studies. Schizophr Bull  2013,39(1),33-42","journal-title":"Schizophr Bull"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1440-1819.2012.02397.x","volume":"66","author":"Ota M.","year":"2012","unstructured":"Ota M.; Sato N.; Ishikawa M.; Hori H.; Sasayama D.; Hattori K.; Teraishi T.; Obu S.; Nakata Y.; Nemoto K.; Moriguchi Y.; Hashimoto R.; Kunugi H.; Discrimination of female schizophrenia patients from healthy women using multiple structural brain measures obtained with voxel\u2010based morphometry. Psychiatry Clin Neurosci  2012,66(7),611-617","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41591-020-0793-8","volume":"26","author":"Li A.","year":"2020","unstructured":"Li A.; Zalesky A.; Yue W.; Howes O.; Yan H.; Liu Y.; A neuroimaging biomarker for striatal dysfunction in schizophrenia. Nat Med  2020,26,558","journal-title":"Nat Med"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biopsych.2016.08.030","volume":"82","author":"Ivleva E.I.","year":"2017","unstructured":"Ivleva E.I.; Clementz B.A.; Dutcher A.M.; Arnold S.J.M.; Jeon-Slaughter H.; Aslan S.; Witte B.; Poudyal G.; Lu H.; Meda S.A.; Pearlson G.D.; Sweeney J.A.; Keshavan M.S.; Tamminga C.A.; Brain structure biomarkers in the psychosis biotypes: Findings from the bipolar-schizophrenia network for intermediate phenotypes. Biol Psychiatry  2017,82(1),26-39","journal-title":"Biol Psychiatry"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12974-020-1724-9","volume":"17","author":"Bai Y.M.","year":"2020","unstructured":"Bai Y.M.; Chen M.H.; Hsu J.W.; Huang K.L.; Tu P.C.; Chang W.C.; Su T.P.; Li C.T.; Lin W.C.; Tsai S.J.; A comparison study of metabolic profiles, immunity, and brain gray matter volumes between patients with bipolar disorder and depressive disorder. J Neuroinflammation  2020,17(1),42","journal-title":"J Neuroinflammation"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/mp.2017.89","volume":"23","author":"Birnbaum R.","year":"2018","unstructured":"Birnbaum R.; Jaffe A.E.; Chen Q.; Shin J.H.; Schubert C.R.; O\u2019Donnell P.; Quan J.; Wendland J.R.; Xi H.S.; Winslow A.R.; Domenici E.; Essioux L.; Kam-Thong T.; Airey D.C.; Calley J.N.; Collier D.A.; Wang H.; Eastwood B.; Ebert P.; Liu Y.; Nisenbaum L.; Ruble C.; Scherschel J.; Smith R.M.; Qian H-R.; Merchant K.; Didriksen M.; Matsumoto M.; Saito T.; Brandon N.J.; Cross A.J.; Wang Q.; Manji H.; Kolb H.; Furey M.; Drevets W.C.; Heon Shin J.; Jaffe A.E.; Jia Y.; Straub R.E.; Deep-Soboslay A.; Hyde T.M.; Kleinman J.E.; Weinberger D.R.; Kleinman J.E.; Hyde T.M.; Weinberger D.R.; Investigating the neuroimmunogenic architecture of schizophrenia. Mol Psychiatry  2018,23(5),1251-1260","journal-title":"Mol Psychiatry"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/01.wnl.0000171450.97464.49","volume":"65","author":"Dickerson B.C.","year":"2005","unstructured":"Dickerson B.C.; Salat D.H.; Greve D.N.; Chua E.F.; Rand-Giovannetti E.; Rentz D.M.; Bertram L.; Mullin K.; Tanzi R.E.; Blacker D.; Albert M.S.; Sperling R.A.; Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology  2005,65(3),404-411","journal-title":"Neurology"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/archpsyc.61.8.774","volume":"61","author":"Brown A.S.","year":"2004","unstructured":"Brown A.S.; Begg M.D.; Gravenstein S.; Schaefer C.A.; Wyatt R.J.; Bresnahan M.; Babulas V.P.; Susser E.S.; Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry   https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/4820402004,61(8),774-780","journal-title":"Arch Gen Psychiatry"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.schres.2010.05.014","volume":"121","author":"Ellman L.M.","year":"2010","unstructured":"Ellman L.M.; Deicken R.F.; Vinogradov S.; Kremen W.S.; Poole J.H.; Kern D.M.; Tsai W.Y.; Schaefer C.A.; Brown A.S.; Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res  2010,121(1-3),46-54","journal-title":"Schizophr Res"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamapsychiatry.2022.0407","volume":"79","author":"Williams J.A.","year":"2022","unstructured":"Williams J.A.; Burgess S.; Suckling J.; Lalousis P.A.; Batool F.; Griffiths S.L.; Palmer E.; Karwath A.; Barsky A.; Gkoutos G.V.; Wood S.; Barnes N.M.; David A.S.; Donohoe G.; Neill J.C.; Deakin B.; Khandaker G.M.; Upthegrove R.; Rogers J.C.; Mondelli V.; Dazzan P.; Pariante C.; MacCabe J.; Egerton A.; Jones P.; Bullmore E.; Koutsouleris N.; Meisenzahl E.; Cotter D.; Harrison N.; Inflammation and brain structure in schizophrenia and other neuropsychiatric disorders. JAMA Psychiatry  2022,79(5),498-507","journal-title":"JAMA Psychiatry"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3389\/fimmu.2018.02230","volume":"9","author":"Jacomb I.","year":"2018","unstructured":"Jacomb I.; Stanton C.; Vasudevan R.; Powell H.; O\u2019Donnell M.; Lenroot R.; Bruggemann J.; Balzan R.; Galletly C.; Liu D.; Weickert C.S.; Weickert T.W.; C-Reactive protein: Higher during acute psychotic episodes and related to cortical thickness in schizophrenia and healthy controls. Front Immunol  2018,9,2230","journal-title":"Front Immunol"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1192\/bjp.bp.111.092098","volume":"200","author":"Chen S.J.","year":"2012","unstructured":"Chen S.J.; Chao Y.L.; Chen C.Y.; Chang C.M.; Wu E.C.H.; Wu C.S.; Yeh H.H.; Chen C.H.; Tsai H.J.; Prevalence of autoimmune diseases in in-patients with schizophrenia: Nationwide population-based study. Br J Psychiatry  2012,200(5),374-380","journal-title":"Br J Psychiatry"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","volume":"7","author":"Miller B.J.","year":"2014","unstructured":"Miller B.J.; Culpepper N.; Rapaport M.H.; C-reactive protein levels in schizophrenia: A review and meta-analysis. Clin Schizophr Relat Psychoses  2014,7(4),223-230","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.psychres.2006.07.011","volume":"149","author":"Fan X.","year":"2007","unstructured":"Fan X.; Pristach C.; Liu E.Y.; Freudenreich O.; Henderson D.C.; Goff D.C.; Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res  2007,149(1-3),267-271","journal-title":"Psychiatry Res"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/08039488.2014.984755","volume":"69","author":"Wysoki\u0144ski A.","year":"2015","unstructured":"Wysoki\u0144ski A.; Margulska A.; Strzelecki D.; K\u0142oszewska I.; Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry  2015,69(5),346-353","journal-title":"Nord J Psychiatry"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/NDT.S284149","volume":"16","author":"Pan L.H.","year":"2020","unstructured":"Pan L.H.; Qian M.; Qu W.; Tang Q.; Yan Y.; Serum c-reactive protein in patients with deficit schizophrenia and the relationship with cognitive function. Neuropsychiatr Dis Treat  2020,16,2891-2897","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1161\/01.ATV.0000100113.47260.EB","volume":"23","author":"Kluft C.","year":"2003","unstructured":"Kluft C.; de Maat M.P.M.; Genetics of C-reactive protein: New possibilities and complications. Arterioscler Thromb Vasc Biol  2003,23(11),1956-1959","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ejmg.2015.10.008","volume":"58","author":"Kotlar A.V.","year":"2015","unstructured":"Kotlar A.V.; Mercer K.B.; Zwick M.E.; Mulle J.G.; New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent findings. Eur J Med Genet  2015,58(12),704-714","journal-title":"Eur J Med Genet"},{"key":"ref=207","first-page":"17","volume":"7","author":"Freedman R.","year":"2022","unstructured":"Freedman R.; Ross R.; Leonard S.; Myles-Worsley M.; Adams C.E.; Waldo M.; Early biomarkers of psychosis. Frreedman  2022,7,17-29","journal-title":"Frreedman"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0006-8993(96)01404-7","volume":"751","author":"Porter R.H.P.","year":"1997","unstructured":"Porter R.H.P.; Eastwood S.L.; Harrison P.J.; Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res  1997,751(2),217-231","journal-title":"Brain Res"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/1098-1063(2000)10:3<213:AID-HIPO2>3.0.CO;2-Q","volume":"10","author":"Zilles K.","year":"2000","unstructured":"Zilles K.; Wu J.; Crusio W.E.; Schwegler H.; Water maze and radial maze learning and the density of binding sites of glutamate, GABA, and serotonin receptors in the hippocampus of inbred mouse strains. Hippocampus  2000,10(3),213-225","journal-title":"Hippocampus"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.schres.2011.09.029","volume":"134","author":"Zhai J.","year":"2012","unstructured":"Zhai J.; Cheng L.; Dong J.; Shen Q.; Zhang Q.; Chen M.; Gao L.; Chen X.; Wang K.; Deng X.; Xu Z.; Ji F.; Liu C.; Li J.; Dong Q.; Chen C.; S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr Res  2012,134(1),89-94","journal-title":"Schizophr Res"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.psychres.2008.01.002","volume":"167","author":"Schroeter M.L.","year":"2009","unstructured":"Schroeter M.L.; Abdul-Khaliq H.; Krebs M.; Diefenbacher A.; Blasig I.E.; Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia \u2014 Original research and meta-analysis. Psychiatry Res  2009,167(1-2),66-72","journal-title":"Psychiatry Res"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jpsychires.2007.10.001","volume":"42","author":"Steiner J.","year":"2008","unstructured":"Steiner J.; Bernstein H.G.; Bielau H.; Farkas N.; Winter J.; Dobrowolny H.; Brisch R.; Gos T.; Mawrin C.; Myint A.M.; Bogerts B.; S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. J Psychiatr Res  2008,42(10),868-876","journal-title":"J Psychiatr Res"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","volume":"64","author":"van Berckel B.N.","year":"2008","unstructured":"van Berckel B.N.; Bossong M.G.; Boellaard R.; Kloet R.; Schuitemaker A.; Caspers E.; Luurtsema G.; Windhorst A.D.; Cahn W.; Lammertsma A.A.; Kahn R.S.; Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry  2008,64(9),820-822","journal-title":"Biol Psychiatry"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2967\/jnumed.109.066647","volume":"50","author":"Doorduin J.","year":"2009","unstructured":"Doorduin J.; de Vries E.F.J.; Willemsen A.T.M.; de Groot J.C.; Dierckx R.A.; Klein H.C.; Neuroinflammation in schizophrenia-related psychosis: A PET study. J Nucl Med  2009,50(11),1801-1807","journal-title":"J Nucl Med"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41398-018-0102-1","volume":"8","author":"Hoseth E.Z.","year":"2018","unstructured":"Hoseth E.Z.; Krull F.; Dieset I.; M\u00f8rch R.H.; Hope S.; Gardsjord E.S.; Steen N.E.; Melle I.; Brattbakk H.R.; Steen V.M.; Aukrust P.; Djurovic S.; Andreassen O.A.; Ueland T.; Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder. Transl Psychiatry  2018,8(1),55","journal-title":"Transl Psychiatry"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.tins.2007.02.002","volume":"30","author":"Lovestone S.","year":"2007","unstructured":"Lovestone S.; Killick R.; Di Forti M.; Murray R.; Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci  2007,30(4),142-149","journal-title":"Trends Neurosci"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"G129","DOI":"10.1152\/ajpgi.00515.2004","volume":"289","author":"Sun J.","year":"2005","unstructured":"Sun J.; Hobert M.E.; Duan Y.; Rao A.S.; He T.C.; Chang E.B.; Madara J.L.; Crosstalk between NF-\u03baB and \u03b2-catenin pathways in bacterial-colonized intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol  2005,289(1),G129-G137","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/1871527311312010012","volume":"12","author":"Melis M.","year":"2013","unstructured":"Melis M.; Carta G.; Pistis M.; Banni S.; Physiological role of peroxisome proliferator-activated receptors type \u03b1 on dopamine systems. CNS Neurol Disord Drug Targets  2013,12(1),70-77","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/mp.2015.148","volume":"21","author":"McCullumsmith R.E.","year":"2016","unstructured":"McCullumsmith R.E.; O\u2019Donovan S.M.; Drummond J.B.; Benesh F.S.; Simmons M.; Roberts R.; Lauriat T.; Haroutunian V.; Meador-Woodruff J.H.; Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons? Mol Psychiatry  2016,21(6),823-830","journal-title":"Mol Psychiatry"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.biopsych.2008.05.001","volume":"64","author":"Karlsson R.M.","year":"2008","unstructured":"Karlsson R.M.; Tanaka K.; Heilig M.; Holmes A.; Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2\/3 agonist. Biol Psychiatry  2008,64(9),810-814","journal-title":"Biol Psychiatry"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-244X-5-6","volume":"5","author":"Hashimoto K.","year":"2005","unstructured":"Hashimoto K.; Engberg G.; Shimizu E.; Nordin C.; Lindstr\u00f6m L.H.; Iyo M.; Elevated glutamine\/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry  2005,5(1),6","journal-title":"BMC Psychiatry"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/mp.2016.122","volume":"22","author":"Kraguljac N.V.","year":"2017","unstructured":"Kraguljac N.V.; Fr\u00f6lich M.A.; Tran S.; White D.M.; Nichols N.; Barton-McArdle A.; Reid M.A.; Bolding M.S.; Lahti A.C.; Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Mol Psychiatry  2017,22(4),562-569","journal-title":"Mol Psychiatry"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/mp.2017.47","volume":"22","author":"Steullet P.","year":"2017","unstructured":"Steullet P.; Cabungcal J-H.; Coyle J.; Didriksen M.; Gill K.; Grace A.A.; Hensch T.K.; LaMantia A-S.; Lindemann L.; Maynard T.M.; Meyer U.; Morishita H.; O\u2019Donnell P.; Puhl M.; Cuenod M.; Do K.Q.; Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol Psychiatry  2017,22(7),936-943","journal-title":"Mol Psychiatry"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/mp.2012.97","volume":"18","author":"Ma T.M.","year":"2013","unstructured":"Ma T.M.; Abazyan S.; Abazyan B.; Nomura J.; Yang C.; Seshadri S.; Sawa A.; Snyder S.H.; Pletnikov M.V.; Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol Psychiatry  2013,18(5),557-567","journal-title":"Mol Psychiatry"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/jnc.13663","volume":"138","author":"Xia M.","year":"2016","unstructured":"Xia M.; Zhu S.; Shevelkin A.; Ross C.A.; Pletnikov M.; DISC 1, astrocytes and neuronal maturation: A possible mechanistic link with implications for mental disorders. J Neurochem  2016,138(4),518-524","journal-title":"J Neurochem"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0925-4927(01)00092-0","volume":"107","author":"Fallgatter A.J.","year":"2001","unstructured":"Fallgatter A.J.; M\u00fcller T.J.; Electrophysiological signs of reduced prefrontal response control in schizophrenic patients. Psychiatry Res Neuroimaging  2001,107(1),19-28","journal-title":"Psychiatry Res Neuroimaging"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2021.10.006","volume":"238","author":"Donaldson K.R.","year":"2021","unstructured":"Donaldson K.R.; Larsen E.M.; Jonas K.; Tramazzo S.; Perlman G.; Foti D.; Mohanty A.; Kotov R.; Mismatch negativity amplitude in first-degree relatives of individuals with psychotic disorders: Links with cognition and schizotypy. Schizophr Res  2021,238,161-169","journal-title":"Schizophr Res"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nicl.2014.07.004","volume":"5","author":"Talati P.","year":"2014","unstructured":"Talati P.; Rane S.; Kose S.; Blackford J.U.; Gore J.; Donahue M.J.; Heckers S.; Increased hippocampal CA1 cerebral blood volume in schizophrenia. Neuroimage Clin  2014,5,359-364","journal-title":"Neuroimage Clin"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/mp.2017.249","volume":"23","author":"Lieberman J.A.","year":"2018","unstructured":"Lieberman J.A.; Girgis R.R.; Brucato G.; Moore H.; Provenzano F.; Kegeles L.; Javitt D.; Kantrowitz J.; Wall M.M.; Corcoran C.M.; Schobel S.A.; Small S.A.; Hippocampal dysfunction in the pathophysiology of schizophrenia: A selective review and hypothesis for early detection and intervention. Mol Psychiatry  2018,23(8),1764-1772","journal-title":"Mol Psychiatry"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41467-019-14122-0","volume":"11","author":"Onwordi E.C.","year":"2020","unstructured":"Onwordi E.C.; Halff E.F.; Whitehurst T.; Mansur A.; Cotel M.C.; Wells L.; Creeney H.; Bonsall D.; Rogdaki M.; Shatalina E.; Reis Marques T.; Rabiner E.A.; Gunn R.N.; Natesan S.; Vernon A.C.; Howes O.D.; Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun  2020,11(1),246","journal-title":"Nat Commun"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamapsychiatry.2017.2943","volume":"74","author":"Jauhar S.","year":"2017","unstructured":"Jauhar S.; Nour M.M.; Veronese M.; Rogdaki M.; Bonoldi I.; Azis M.; Turkheimer F.; McGuire P.; Young A.H.; Howes O.D.; A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry  2017,74(12),1206-1213","journal-title":"JAMA Psychiatry"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamapsychiatry.2016.2619","volume":"73","author":"Thun\u00e9 H.","year":"2016","unstructured":"Thun\u00e9 H.; Recasens M.; Uhlhaas P.J.; The 40-Hz auditory steady-state response in patients with schizophrenia. JAMA Psychiatry  2016,73(11),1145-1153","journal-title":"JAMA Psychiatry"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41386-020-00806-5","volume":"45","author":"Koshiyama D.","year":"2020","unstructured":"Koshiyama D.; Miyakoshi M.; Joshi Y.B.; Molina J.L.; Tanaka-Koshiyama K.; Sprock J.; Braff D.L.; Swerdlow N.R.; Light G.A.; A distributed frontotemporal network underlies gamma-band synchronization impairments in schizophrenia patients. Neuropsychopharmacology  2020,45(13),2198-2206","journal-title":"Neuropsychopharmacology"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1073\/pnas.0308455101","volume":"101","author":"Jackson M.E.","year":"2004","unstructured":"Jackson M.E.; Homayoun H.; Moghaddam B.; NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA  2004,101(22),8467-8472","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tips.2011.05.001","volume":"32","author":"Lodge D.J.","year":"2011","unstructured":"Lodge D.J.; Grace A.A.; Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci  2011,32(9),507-513","journal-title":"Trends Pharmacol Sci"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680266389476250818112814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/246701\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680266389476250818112814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:15:29Z","timestamp":1785989729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/246701\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":235,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115680266389476250818112814","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.169296182.23817881\/v2","asserted-by":"object"}]},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}